Days At A Glance Speakers Session Type Search
Type

    09:00 - 11:00 
    REGISTRATION
    11:00 - 13:00 
    Symposium 1: GENETIC REGULATION OF PITUITARY TUMOURIGENESIS
    DEVELOPED WITH THE SOCIETY FOR ENDOCRINOLOGY'S PITUITARY SPECIAL INTEREST GROUP AND THE ASSOCIATION FOR MULTIPLE ENDOCRINE NEOPLASIA DISORDERS
    QUEEN'S SUITE A
    Chairs: R Fowkes (London) & H Chahal (London)
    S1.1
    Symposium 1: GENETIC REGULATION OF PITUITARY TUMOURIGENESIS
    Genetic models of pituitary disease in MEN1
    Oxford, United Kingdom
    S1.2
    Symposium 1: GENETIC REGULATION OF PITUITARY TUMOURIGENESIS
    Modelling pituitary tumours in zebrafish
    Los Angeles, USA
    S1.3
    Symposium 1: GENETIC REGULATION OF PITUITARY TUMOURIGENESIS
    Mouse model of craniopharyngioma
    S1.4
    Symposium 1: GENETIC REGULATION OF PITUITARY TUMOURIGENESIS
    Molecular signatures of pituitary tumours

    Unknown speaker

    London, UK
    11:00 - 13:00 
    Symposium 2: ENDOPLASMIC RETICULUM STRESS IN METABOLIC DISEASE AND OBESITY
    Stress caused by unfolded and misfolded proteins in the endoplasmic reticulum (so called "ER stress") intersects with metabolic disease at multiple levels
    QUEEN'S SUITE B
    Chairs: P Chapple (London) & E Harno (Manchester)
    S2.1
    Symposium 2: ENDOPLASMIC RETICULUM STRESS IN METABOLIC DISEASE AND OBESITY
    ER stress and metabolic regulation
    S2.2
    Symposium 2: ENDOPLASMIC RETICULUM STRESS IN METABOLIC DISEASE AND OBESITY
    ER stress, leptin signalling and obesity
    Boston, USA
    S2.3
    Symposium 2: ENDOPLASMIC RETICULUM STRESS IN METABOLIC DISEASE AND OBESITY
    Lipotoxic endoplasmic reticulum stress and pancreatic beta-cell demise in type 2 diabetes
    Brussels, Belgium
    S2.4
    Symposium 2: ENDOPLASMIC RETICULUM STRESS IN METABOLIC DISEASE AND OBESITY
    Patients with monogenic diabetes resulting from ER stress of the pancreatic beta-cell
    11:00 - 13:00 
    Symposium 3: TESTOSTERONE IN MEN: HOW LOW CAN YOU GO?
    DEVELOPED WITH THE SOCIETY FOR ENDOCRINOLOGY'S ANDROLOGY SPECIAL INTEREST GROUP AND THE KLINEFELTER'S SYNDROME ASSOCIATION
    MAIN AUDITORIUM
    Chairs: R Quinton (Newcastle) & A Theodoraki (London)
    S3.1
    Symposium 3: TESTOSTERONE IN MEN: HOW LOW CAN YOU GO?
    Is there a male menopause - lesson from the European Male Ageing Study
    S3.2
    Symposium 3: TESTOSTERONE IN MEN: HOW LOW CAN YOU GO?
    Does testosterone treatment increase mortality in elderly men?
    Boston, USA
    S3.3
    Symposium 3: TESTOSTERONE IN MEN: HOW LOW CAN YOU GO?
    What is the best form of testosterone replacement?
    S3.4
    Symposium 3: TESTOSTERONE IN MEN: HOW LOW CAN YOU GO?
    Can testosterone therapy be stopped in some hypogonadal patients?
    Helsinki, Finland
    13:00 - 13:30 
    LUNCH
    HALL Q
    13:30 - 15:30 
    Applied Physiology Workshop:
    NANOMEDICINE
    QUEEN'S SUITE B
    Chairs: M Gurnell (Cambridge) & R Fowkes (London)
    AP1.1
    Applied Physiology Workshop:
    Magnetic nanoparticles for drug delivery
    AP1.2
    Applied Physiology Workshop:
    Nanoparticles as imaging agents
    St Louis, USA
    AP1.3
    Applied Physiology Workshop:
    Nanomedicine in clinical diabetes
    13:30 - 15:30 
    Oral Communications 1: YOUNG ENDOCRINOLOGISTS' PRIZE SESSION
    QUEEN'S SUITE A
    Chairs: G Karsenty (New York, NY, USA) & J Newell-Price (Sheffield)
    OC1.1
    Oral Communications 1: YOUNG ENDOCRINOLOGISTS' PRIZE SESSION
    Functional characterisation and translational clinical applications of kisspeptin-10
    OC1.2
    Oral Communications 1: YOUNG ENDOCRINOLOGISTS' PRIZE SESSION
    Structure-function analysis of calcium-sensing receptor (CaSR) mutations reveal clustering at calcium binding sites of the extracellular bilobed venus flytrap domain
    OC1.3
    Oral Communications 1: YOUNG ENDOCRINOLOGISTS' PRIZE SESSION
    Effect of selenium status on the skeleton in post-menopausal women: the OPUS study
    OC1.4
    Oral Communications 1: YOUNG ENDOCRINOLOGISTS' PRIZE SESSION
    The thyroid hormone receptor-coactivator interface mediates negative feedback regulation of the human pituitary-thyroid axis
    Cambridge
    OC1.5
    Oral Communications 1: YOUNG ENDOCRINOLOGISTS' PRIZE SESSION
    Growth retardation and severe constipation due to the first human, dominant negative thyroid hormone receptor alpha mutation
    OC1.6
    Oral Communications 1: YOUNG ENDOCRINOLOGISTS' PRIZE SESSION
    A homozygous glutathione peroxidase 1 mutation, p.Arg130-Leu133del, in a patient with familial glucocorticoid deficiency
    OC1.7
    Oral Communications 1: YOUNG ENDOCRINOLOGISTS' PRIZE SESSION
    Progressive adrenal insufficiency and 46,XY DSD caused by two novel mutations in the cytochrome P450 side-chain cleavage (CYP11A1) gene
    OC1.8
    Oral Communications 1: YOUNG ENDOCRINOLOGISTS' PRIZE SESSION
    Metastasis related methyltransferase 1 (Merm1)/WBSCR22 regulates glucocorticoid receptor (GR) function
    13:30 - 15:30 
    Symposium 4: ADVANCES IN THE MANAGEMENT OF DIFFERENTIATED THYROID CANCER
    Thyroid cancer management is evolving to reflect novel developments in imaging, cytology, molecular biology and the outcome of trials evaluating low versus high dose radioiodine therapy
    MAIN AUDITORIUM
    Chairs: K Boelaert (Birmingham) & P Newey (Oxford)
    S4.1
    Symposium 4: ADVANCES IN THE MANAGEMENT OF DIFFERENTIATED THYROID CANCER
    Can imaging predict malignancy in a thyroid nodule?
    S4.2
    Symposium 4: ADVANCES IN THE MANAGEMENT OF DIFFERENTIATED THYROID CANCER
    Predictive value of cytology and molecular markers in thyroid cancer
    S4.3
    Symposium 4: ADVANCES IN THE MANAGEMENT OF DIFFERENTIATED THYROID CANCER
    The place of radioiodine in the management of thyroid cancer
    Rochester, USA
    S4.4
    Symposium 4: ADVANCES IN THE MANAGEMENT OF DIFFERENTIATED THYROID CANCER
    Novel treatments - from PCR to patient
    15:30 - 16:00 
    TEA & COFFEE
    HALL Q
    16:00 - 18:00 
    Oral Communications 2: REPRODUCTION AND BONE
    QUEEN'S SUITE B
    Chairs: A McNeilly (Edinburgh) & E Vasilopoulou (Birmingham)
    OC2.1
    Oral Communications 2: REPRODUCTION AND BONE
    The expression of kisspeptin and kisspeptin receptor is altered in pre-eclampsia
    OC2.2
    Oral Communications 2: REPRODUCTION AND BONE
    Contrasting effects of kisspeptin-10 between men and women reveal sexual dimorphism in the hypothalamic regulation of human reproduction
    OC2.3
    Oral Communications 2: REPRODUCTION AND BONE
    Kissorphin, a hexapeptide derivative of kisspeptin, acts via neuropeptide FF receptors to inhibit cyclic adenosine monophosphate release but has no gonadotrophin-releasing hormone releasing activity
    OC2.4
    Oral Communications 2: REPRODUCTION AND BONE
    ERβ and GPR30 mediate distinct and opposite oestrogenic influences on microglial phagocytosis of apoptotic neuronal cells
    OC2.5
    Oral Communications 2: REPRODUCTION AND BONE
    Nutrient regulation of growth factor signalling in human placenta
    OC2.6
    Oral Communications 2: REPRODUCTION AND BONE
    Identification of microRNAs involved in regulating growth factor signalling in the first trimester placenta
    OC2.7
    Oral Communications 2: REPRODUCTION AND BONE
    Increased cardiovascular events in women with polycystic ovary syndrome: retrospective analysis of a large database
    OC2.8
    Oral Communications 2: REPRODUCTION AND BONE
    A calcium-sensing receptor (CaSR) variant, Glu250Lys, present in familial hypocalciuric hypercalcaemia (FHH) and autosomal dominant hypocalcaemic hypercalciuria (ADHH) probands represents a functionally neutral polymorphism: lessons for CaSR mutational analysis
    16:00 - 18:00 
    Symposium 5: SPRINT OR MARATHON? MUSCLING IN ON THE OLYMPICS
    Muscle is recognised as important endocrine organ and target for the treatment of metabolic syndrome. This symposium will explore the breadth of our new understanding of basic metabolism and investigative clinical data that is currently emerging.
    QUEEN'S SUITE A
    Chairs: G Lavery (Birmingham) & N Morton (Edinburgh)
    S5.1
    Symposium 5: SPRINT OR MARATHON? MUSCLING IN ON THE OLYMPICS
    Muscles and their myokines
    Copenhagen, Denmark
    S5.2
    Symposium 5: SPRINT OR MARATHON? MUSCLING IN ON THE OLYMPICS
    Exercise effects on fat metabolism and insulin sensitivity in human muscle
    S5.3
    Symposium 5: SPRINT OR MARATHON? MUSCLING IN ON THE OLYMPICS
    Novel signalling mechanisms controlling glycogen homeostasis in muscle
    S5.4
    Symposium 5: SPRINT OR MARATHON? MUSCLING IN ON THE OLYMPICS
    Mitochondrial dysfunction and muscle disease
    16:00 - 18:00 
    Clinical Management Workshop 1: THE LATE CONSEQUENCES OF CANCER THERAPY IN ADULTS
    Two million people in the UK are living with or beyond cancer. Many are at risk of endocrinopathy
    SUPPORTED BY CLINICAL ENDOCRINOLOGY, DEVELOPED WITH THE SOCIETY FOR ENDOCRINOLOGY'S LATE EFFECTS OF CANCER THERAPY SPECIAL INTEREST GROUP
    MAIN AUDITORIUM
    Chairs: M Druce (London) & A Kennedy (Birmingham)
    CM1.1
    Clinical Management Workshop 1: THE LATE CONSEQUENCES OF CANCER THERAPY IN ADULTS
    The follow up of cancer survivors
    CM1.2
    Clinical Management Workshop 1: THE LATE CONSEQUENCES OF CANCER THERAPY IN ADULTS
    The impact of cancer treatment on pituitary function
    CM1.3
    Clinical Management Workshop 1: THE LATE CONSEQUENCES OF CANCER THERAPY IN ADULTS
    The impact of cancer treatment on fertility and pregnancy
    CM1.4
    Clinical Management Workshop 1: THE LATE CONSEQUENCES OF CANCER THERAPY IN ADULTS
    The late consequences of cancer therapy to the thyroid
    18:00 - 18:10 
    BREAK
    18:10 - 19:10 
    YOUNG ENDOCRINOLOGISTS' PRIZE LECTURES
    MAIN AUDITORIUM
    Chairs: K Chapman (Edinburgh) & A Grossman (London)
    YEP1.1
    YOUNG ENDOCRINOLOGISTS' PRIZE LECTURES
    Challenging the dogma: Tissue specific regulation of insulin action
    YEP1.2
    YOUNG ENDOCRINOLOGISTS' PRIZE LECTURES
    Quantifying in vivo extra-adrenal cortisol production and dysregulation in human metabolic disease
    Edinburgh, UK
    19:10 - 21:00 
    WELCOME RECEPTION
    HALL Q
    19:45 - 23:45 
    YOUNG ENDOCRINOLOGISTS' SOCIAL EVENING
    HALL D

    07:00 - 07:15 
    BREAKFAST
    MAIN AUDITORIUM FOYER & QUEEN'S SUITE FOYER
    07:15 - 08:00 
    MEET THE EXPERT 1
    Therapeutic management of adults with CAH
    SUPPORTED BY CLINICAL ENDOCRINOLOGY
    QUEEN'S SUITE A
    Chair: S Ahmed (Glasgow)
    Expert: W Arlt (Birmingham)
    MTE1
    MEET THE EXPERT 1
    Therapeutic management of adults with CAH
    07:15 - 08:00 
    MEET THE EXPERT 2
    Amiodarone
    SUPPORTED BY CLINICAL ENDOCRINOLOGY
    QUEEN'S SUITE B
    Chair: A Weetman (Sheffield)
    Expert: M Vanderpump (London)
    MTE2
    MEET THE EXPERT 2
    Amiodarone
    07:15 - 08:00 
    MEET THE EXPERT 3
    Preventing and managing long term complications of acromegaly
    SUPPORTED BY CLINICAL ENDOCRINOLOGY
    MAIN AUDITORIUM
    Chair: R Murray (Leeds)
    Expert: K Meeran (London)
    MTE3
    MEET THE EXPERT 3
    Preventing and managing long term complications of acromegaly
    08:15 - 10:15 
    Symposium 6: INHIBITING STEROID ENZYMES TO TREAT COMMON DISEASE
    Novel drugs targeting steroid synthesis and metabolism provide new avenues for treating human diseases
    QUEEN'S SUITE A
    Chairs: W Arlt (Birmingham) & S Alvarez-Madrazo (Glasgow)
    S6.1
    Symposium 6: INHIBITING STEROID ENZYMES TO TREAT COMMON DISEASE
    Ageing gracefully - the role of 11beta-HSD1
    S6.2
    Symposium 6: INHIBITING STEROID ENZYMES TO TREAT COMMON DISEASE
    Old drugs for new targets - CYP11B2 inhibitors for hypertension
    Saarbrucken, Germany
    S6.3
    Symposium 6: INHIBITING STEROID ENZYMES TO TREAT COMMON DISEASE
    Dual aromatase and steroid sulfatase inhibition in breast cancer
    S6.4
    Symposium 6: INHIBITING STEROID ENZYMES TO TREAT COMMON DISEASE
    Potential prostate cancer drug target: bioactivation of androstanediol by conversion to dihydrotestosterone
    Chapel Hill, USA
    08:15 - 10:15 
    Oral Communications 3: OBESITY, THYROID AND ADDISON'S DISEASE
    QUEEN'S SUITE B
    Chairs: A Brooke (Exeter) & N Schoenmakers (Cambridge)
    OC3.1
    Oral Communications 3: OBESITY, THYROID AND ADDISON'S DISEASE
    Metformin in obese children and adolescents (MOCA) trial
    OC3.2
    Oral Communications 3: OBESITY, THYROID AND ADDISON'S DISEASE
    Post-prandial high fat intake leads to acute exposure to circulating endotoxin in type 2 diabetes mellitus subjects
    OC3.3
    Oral Communications 3: OBESITY, THYROID AND ADDISON'S DISEASE
    Risk of diabetes, cancer, large vessel disease and mortality in young women with polycystic ovary syndrome: a retrospective databased analysis
    OC3.4
    Oral Communications 3: OBESITY, THYROID AND ADDISON'S DISEASE
    Glucose absorption capacity of the mature adipose tissue is increased after Bardet-Biedl syndrome induced ciliary defect in adipocytes' precursors
    Strasbourg, France
    OC3.5
    Oral Communications 3: OBESITY, THYROID AND ADDISON'S DISEASE
    Steroidogenic function following B lymphocyte depletion therapy in new onset autoimmune Addison's disease
    Newcastle, UK
    OC3.6
    Oral Communications 3: OBESITY, THYROID AND ADDISON'S DISEASE
    GATA3 polymorphisms are associated with autoimmune Addison's disease
    OC3.7
    Oral Communications 3: OBESITY, THYROID AND ADDISON'S DISEASE
    Subclinical hypothyroidism is associated with fatigue and impaired functional status in males in the Whickham 20-year follow up cohort
    OC3.8
    Oral Communications 3: OBESITY, THYROID AND ADDISON'S DISEASE
    Dietary factors augment the ability of the proto-oncogene PBF to induce goitrogenesis and hyperplasia in vivo
    08:15 - 10:15 
    Clinical Management Workshop 2: CONTROVERSIES IN AETIOLOGY AND MANAGEMENT OF OSTEOPOROSIS
    SUPPORTED BY CLINICAL ENDOCRINOLOGY AND DEVELOPED WITH THE SOCIETY FOR ENDOCRINOLOGY'S BONE AND MINERAL SPECIAL INTEREST GROUP
    MAIN AUDITORIUM
    Chairs: S Orme (Leeds) & C Higham (Manchester)
    CM2.1
    Clinical Management Workshop 2: CONTROVERSIES IN AETIOLOGY AND MANAGEMENT OF OSTEOPOROSIS
    Impact of lifestyle choices on skeletal health
    CM2.2
    Clinical Management Workshop 2: CONTROVERSIES IN AETIOLOGY AND MANAGEMENT OF OSTEOPOROSIS
    Osteoporosis and metabolic bone disease in adolescence
    CM2.3
    Clinical Management Workshop 2: CONTROVERSIES IN AETIOLOGY AND MANAGEMENT OF OSTEOPOROSIS
    Complications of antiresorptive agents

    Unknown speaker

    Holbæk, Denmark
    CM2.4
    Clinical Management Workshop 2: CONTROVERSIES IN AETIOLOGY AND MANAGEMENT OF OSTEOPOROSIS
    New and emerging therapies for osteoporosis
    10:15 - 10:40 
    TEA & COFFEE
    HALL Q
    10:40 - 11:20 
    SOCIETY FOR ENDOCRINOLOGY DALE MEDAL LECTURE
    MAIN AUDITORIUM
    Chair: J Buckingham (London)
    PL1
    SOCIETY FOR ENDOCRINOLOGY DALE MEDAL LECTURE
    Estrogen receptor insensitivity: physiological and clinical consequences
    Durham, USA
    11:20 - 12:00 
    SOCIETY FOR ENDOCRINOLOGY HOFFENBERG INTERNATIONAL MEDAL LECTURE
    MAIN AUDITORIUM
    Chair: G Williams (London)
    PL2
    SOCIETY FOR ENDOCRINOLOGY HOFFENBERG INTERNATIONAL MEDAL LECTURE
    Bone as endocrine organ
    New York, USA
    12:00 - 14:00 
    LUNCH & POSTERS
    HALL Q
    14:00 - 16:00 
    Oral Communications 4: Steroids
    QUEEN'S SUITE A
    Chairs: R Bernhardt (Saarbrucken, Germany) & F McManus (Glasgow)
    OC4.1
    Oral Communications 4: Steroids
    Increased 11β-hydroxysteroid dehydrogenase type 1 activity is associated with the adverse expression of glucocorticoid target genes in ageing human skin

    Unknown speaker

    Leeds, United Kingdom
    OC4.2
    Oral Communications 4: Steroids
    Age-dependent increase in the expression/activity of 11β-HSD1 in key metabolic tissues may underpin the ageing phenotype, notably sarcopenia
    OC4.3
    Oral Communications 4: Steroids
    A hypomorphic H6PD allele is sufficient to rescue the skeletal myopathy but not the lack of 11β-HSd type-1 mediated glucocorticoid regeneration phenotypes of H6PDKO mice
    OC4.4
    Oral Communications 4: Steroids
    Broad phenotypic spectrum of 17a-hydroxylase deficiency: functional characterisation of 4 novel mutations in the CYP17A1 gene
    OC4.5
    Oral Communications 4: Steroids
    A novel repressor mechanism regulating fetal Leydig cell steroidogenesis, pertubation of which results in masculinization disorders
    OC4.6
    Oral Communications 4: Steroids
    Fatty liver in a mouse model of congenital adrenal hyperplasia is driven by peroxisome proliferator-activated receptors
    OC4.7
    Oral Communications 4: Steroids
    Glucocorticoids increase subcutaneous adipose tissue insulin sensitivity in vivo: a randomised double-blind, placebo controlled, cross over study
    OC4.8
    Oral Communications 4: Steroids
    The role of a novel co-regulator in modifying the transcriptional activities of the glucocorticoid receptor
    14:00 - 16:00 
    Symposium 7: LATITUDE: ENDOCRINE CONSEQUENCES OF HUMAN MIGRATION
    As humans have migrated towards the poles, a number of changes have occurred to our endocrine systems which have allowed us to adapt to our new environment, particularly daily and seasonal changes in light intensity and duration. In this symposium we will explore those endocrine systems most affected by latitudinal light levels and our adaptations to overcome these changes
    MAIN AUDITORIUM
    Chairs: D Renshaw (London) & A McNeilly (Edinburgh)
    S7.1
    Symposium 7: LATITUDE: ENDOCRINE CONSEQUENCES OF HUMAN MIGRATION
    The origins and evolution of lactase persistence
    S7.2
    Symposium 7: LATITUDE: ENDOCRINE CONSEQUENCES OF HUMAN MIGRATION
    Melatonin, light and sleep in the Antartic
    S7.3
    Symposium 7: LATITUDE: ENDOCRINE CONSEQUENCES OF HUMAN MIGRATION
    Cortisol and mood - coping with seasons
    S7.4
    Symposium 7: LATITUDE: ENDOCRINE CONSEQUENCES OF HUMAN MIGRATION
    Resurgence of vitamin D deficiency rickets in the UK
    Manchester, UK
    14:00 - 16:00 
    Young Endocrinologists' Symposium: OBTAINING FUNDING AND NETWORKING FOR YOUNG ENDOCRINOLOGISTS
    QUEEN'S SUITE B
    Chairs: V Cabrera-Sharp (London) & S Mirczuk (London)
    YE1.1
    Young Endocrinologists' Symposium: OBTAINING FUNDING AND NETWORKING FOR YOUNG ENDOCRINOLOGISTS
    Obtaining fellowship funding and networking
    Leeds, UK
    YE1.2
    Young Endocrinologists' Symposium: OBTAINING FUNDING AND NETWORKING FOR YOUNG ENDOCRINOLOGISTS
    Pathways in clinical academia, fellowships and networking
    Birmingham, UK
    YE1.3
    Young Endocrinologists' Symposium: OBTAINING FUNDING AND NETWORKING FOR YOUNG ENDOCRINOLOGISTS
    Career opportunities in the States
    YE1.4
    Young Endocrinologists' Symposium: OBTAINING FUNDING AND NETWORKING FOR YOUNG ENDOCRINOLOGISTS
    Trials and tribulations of the university lecturer
    16:00 - 16:30 
    TEA & COFFEE
    HALL Q
    16:30 - 17:30 
    Clinical Debate:
    THIS HOUSE BELIEVES THAT ALL ADRENAL PATIENTS WITH INCIDENTALOMA WHO FAIL TO SUPPRESS CORTISOL AFTER DEXAMETHASONE SHOULD HAVE AN ADRENALECTOMY
    MAIN AUDITORIUM
    Chair: S Shalet (Manchester)
    For: B Atkinson (Belfast) Against: P Stewart (Birmingham)
    16:30 - 17:15 
    MEET THE EXPERT 1 - REPEAT
    Therapeutic management of adults with CAH
    SUPPORTED BY CLINICAL ENDOCRINOLOGY
    HALL D
    Chair: S Ahmed (Glasgow)
    Expert: W Arlt (Birmingham)
    MTE1
    MEET THE EXPERT 1 - REPEAT
    Therapeutic management of adults with CAH
    16:30 - 18:30 
    Oral Communications 5: GROWTH, TUMOURS AND PITUITARY
    QUEEN'S SUITE A
    Chairs: J Webster (Sheffield) & V Smith (Birmingham)
    OC5.1
    Oral Communications 5: GROWTH, TUMOURS AND PITUITARY
    Human growth is regulated by an ubiquitination pathway including CUL7, OBSL1 and CCDC8
    OC5.2
    Oral Communications 5: GROWTH, TUMOURS AND PITUITARY
    A network analysis of gene expression through childhood highlights changes related to age and growth
    OC5.3
    Oral Communications 5: GROWTH, TUMOURS AND PITUITARY
    Long term experience of 131I-MIBG therapy in the treatment of neuroendocrine tumours: has it improved survival and what are the long term sequelae?
    OC5.4
    Oral Communications 5: GROWTH, TUMOURS AND PITUITARY
    Steroid metabolomics in adrenocortical carcinoma reveal mitotane as an inducer of CYP3A4 and an inhibitor of 5alpha-reductase activity with major implications for drug metabolism and hydrocortisone replacement
    OC5.5
    Oral Communications 5: GROWTH, TUMOURS AND PITUITARY
    Role of the hypoxic signalling pathways in the histopathological prediction of malignancy in phaeochromocytomas and paragangliomas
    OC5.6
    Oral Communications 5: GROWTH, TUMOURS AND PITUITARY
    SUMOylation genes in pituitary gonadotrophs: wrestling with GnRH signalling
    OC5.7
    Oral Communications 5: GROWTH, TUMOURS AND PITUITARY
    The role of the familialpituitary adenoma gene, AIP, in the proliferative and invasive activity of a malignant pancreatic cell line
    OC5.8
    Oral Communications 5: GROWTH, TUMOURS AND PITUITARY
    Control of GH and IGF1 in acromegaly in the UK: responses to medical treatment
    16:30 - 18:30 
    Symposium 8: SMALL MOLECULES, BIG EFFECTS: THE EMERGING ROLE FOR MICRO RNAS
    MicroRNAs have emerged in recent years as key regulators in cancer and endocrine disease. They dramatically modify gene expression at the post-transcriptional stage
    QUEEN'S SUITE B
    Chairs: M Westwood (Manchester) & S Wood (Glasgow)
    S8.1
    Symposium 8: SMALL MOLECULES, BIG EFFECTS: THE EMERGING ROLE FOR MICRO RNAS
    MicroRNA: an introduction
    S8.2
    Symposium 8: SMALL MOLECULES, BIG EFFECTS: THE EMERGING ROLE FOR MICRO RNAS
    MicroRNA regulation of the IGF axis
    Leeds, UK
    S8.3
    Symposium 8: SMALL MOLECULES, BIG EFFECTS: THE EMERGING ROLE FOR MICRO RNAS
    MicroRNA and the beta-cell
    Berlin, Germany
    S8.4
    Symposium 8: SMALL MOLECULES, BIG EFFECTS: THE EMERGING ROLE FOR MICRO RNAS
    MicroRNA in the diagnosis and therapy of endcorine cancers
    17:15 - 18:00 
    MEET THE EXPERT 2 - REPEAT
    Amiodarone
    SUPPORTED BY CLINICAL ENDOCRINOLOGY
    HALL D
    Chair: A Weetman (Sheffield)
    Expert: M Vanderpump (London)
    MTE2
    MEET THE EXPERT 2 - REPEAT
    Amiodarone
    18:40 - 19:10 
    SOCIETY FOR ENDOCRINOLOGY TRANSATLANTIC MEDAL
    MAIN AUDITORIUM
    Chair: P Stewart (Birmingham)
    PL3
    SOCIETY FOR ENDOCRINOLOGY TRANSATLANTIC MEDAL
    Metabolism to epigenetics: the circadian clock link
    Irvine, USA
    19:40 - 00:00 
    CONFERENCE DINNER
    ROYAL HALL

    07:00 - 07:15 
    BREAKFAST
    QUEEN'S SUITE FOYER
    07:15 - 08:00 
    MEET THE EXPERT 4
    Management of persistent TSH elevation in hypothyroid patients
    SUPPORTED BY CLINICAL ENDOCRINOLOGY AND THE BRITISH THYROID FOUNDATION
    QUEEN'S SUITE A
    Chair: J Wass (Oxford)
    Expert: A Allahabadia (Sheffield)
    MTE4
    MEET THE EXPERT 4
    Management of persistent TSH elevation in hypothyroid patients
    07:15 - 08:00 
    MEET THE EXPERT 5
    The surgical approaches to MEN1 - what the endocrinologist needs to know
    SUPPORTED BY CLINICAL ENDOCRINOLOGY
    QUEEN'S SUITE B
    Chair: S Ball (Newcastle)
    Expert: B Harrison (Sheffield)
    MTE5
    MEET THE EXPERT 5
    The surgical approaches to MEN1 - what the endocrinologist needs to know
    Sheffield, UK
    08:00 - 08:10 
    BREAKFAST
    MAIN AUDITORIUM FOYER
    08:10 - 08:55 
    SOCIETY FOR ENDOCRINOLOGY ANNUAL GENERAL MEETING
    MAIN AUDITORIUM
    09:00 - 11:00 
    Symposium 9: DEVELOPMENTAL PROGRAMMING OF ENDOCRINE DISEASE
    It’s not what I eat, it’s what my mother ate. Can maternal lifestyle or nutrition programme life-long metabolic and endocrine problems in their offspring.
    QUEEN'S SUITE A
    Chairs: A Fowden (Cambridge) & O Brand (Oxford)
    S9.1
    Symposium 9: DEVELOPMENTAL PROGRAMMING OF ENDOCRINE DISEASE
    Developmental programming of type 2 diabetes
    S9.2
    Symposium 9: DEVELOPMENTAL PROGRAMMING OF ENDOCRINE DISEASE
    Neuroendocrine origins of obesity
    Los Angeles, USA
    S9.3
    Symposium 9: DEVELOPMENTAL PROGRAMMING OF ENDOCRINE DISEASE
    The foetus or the placenta? Targets of glucorticoid programming
    S9.4
    Symposium 9: DEVELOPMENTAL PROGRAMMING OF ENDOCRINE DISEASE
    Obesity in pregnancy: implications for the next generation
    Laramie, USA
    09:00 - 11:00 
    Symposium 10:
    CURRENT CONCEPTS AND MANAGEMENT OF PHAEOCHROMOCYTOMA
    SUPPORTED BY THE ASSOCIATION FOR MULTIPLE ENDOCRINE NEOPLASIA DISORDERS
    MAIN AUDITORIUM
    Chairs: J Connell (Dundee) & U Srirangalingam (London)
    S10.1
    Symposium 10:
    Genetics and epidemiology
    S10.2
    Symposium 10:
    Molecular mechanisms of phaeochromocytoma and tumorigenesis
    San Antonio, USA
    S10.3
    Symposium 10:
    Laboratory assessment and diagnostic imaging
    Nijmegen, The Netherlands
    S10.4
    Symposium 10:
    Novel therapies for malignant phaeochromocytomas and paragangliomas
    Paris, France
    09:00 - 11:00 
    Nurses' Session 1:
    THYROID EYE DISEASE
    SUPPORTED BY THE THYROID EYE DISEASE CHARITABLE TRUST
    QUEEN'S SUITE B
    Chairs: D Wright (Bradford) & N Ellis (Bradford)
    N1.1
    Nurses' Session 1:
    Thyroid Eye Disease - presentation and treatment
    N1.2
    Nurses' Session 1:
    Thyroid Eye Disease
    N1.3
    Nurses' Session 1:
    Thyroid Eye Disease
    11:00 - 11:30 
    TEA & COFFEE
    11:30 - 12:00 
    SOCIETY FOR ENDOCRINOLOGY EUROPEAN MEDAL LECTURE
    MAIN AUDITORIUM
    Chair: M Korbonits (London)
    PL4
    SOCIETY FOR ENDOCRINOLOGY EUROPEAN MEDAL LECTURE
    GLP-1 therapy of type 2 diabetes - current status
    Copenhagen, Denmark
    12:00 - 12:30 
    SOCIETY FOR ENDOCRINOLOGY JUBILEE MEDAL LECTURE
    MAIN AUDITORIUM
    Chair: G Williams (London)
    PL5
    SOCIETY FOR ENDOCRINOLOGY JUBILEE MEDAL LECTURE
    Acromegaly - improving outcomes
    12:30 - 13:45 
    LUNCH
    HALL Q
    13:45 - 15:45 
    Symposium 11: NOVEL LESSONS FROM MINERALOCORTICOID EXCESS
    Recent breakthroughs from the genetics of mineralocorticoid hypertension
    QUEEN'S SUITE A
    Chairs: E Davies (Glasgow) & E Nogueira (Birmingham)
    S11.1
    Symposium 11: NOVEL LESSONS FROM MINERALOCORTICOID EXCESS
    A difficult TASK: murine models of mineralocorticoid excess
    Regensburg, Germany
    S11.2
    Symposium 11: NOVEL LESSONS FROM MINERALOCORTICOID EXCESS
    Human potassium channel mutations and mineralocorticoid hypertension
    Paris, France
    S11.3
    Symposium 11: NOVEL LESSONS FROM MINERALOCORTICOID EXCESS
    Long term consequences of primary hyperaldosteronism
    S11.4
    Symposium 11: NOVEL LESSONS FROM MINERALOCORTICOID EXCESS
    Therapeutic options for mineralocorticoid hypertension
    13:45 - 15:45 
    Symposium 12: MEDULLARY THYROID CANCER
    Emerging knowledge of the molecular mechanisms in medullary carcinoma of the thyroid is improving our understanding of this condition, which is now impacting on therapy
    MAIN AUDITORIUM
    Chairs: D Bassett (London) & V Smith (Birmingham)
    S12.1
    Symposium 12: MEDULLARY THYROID CANCER
    Molecular pathogenesis of MTC
    Naples, Italy
    S12.2
    Symposium 12: MEDULLARY THYROID CANCER
    RAS mutations in sporadic MTC
    Lisbon, Portugal
    S12.3
    Symposium 12: MEDULLARY THYROID CANCER
    The diagnosis and management of MTC
    S12.4
    Symposium 12: MEDULLARY THYROID CANCER
    Novel targeted therapies for MTC
    Paris, France
    13:45 - 15:45 
    Nurses' Session 2:
    ADDISON'S/PHAEOCHROMOCYTOMAS/CONN'S SYNDROME
    QUEEN'S SUITE B
    Chairs: S Gorick (Norwich) & V Kieffer (Leicester)
    N2.1
    Nurses' Session 2:
    Conn's and phaeochromocytoma
    N2.2
    Nurses' Session 2:
    Nursing case study on phaeochromocytoma
    N2.3
    Nurses' Session 2:
    Introduction to Addison's
    N2.4
    Nurses' Session 2:
    Day-to-day practice on management of steroid replacement
    N2.5
    Nurses' Session 2:
    Living with Addison's
    13:45 - 14:30 
    MEET THE EXPERT 8
    Optogenetics: controlling cells with light
    HALL D
    Chair: R Andrew (Edinburgh)
    Expert: R Allemann (Cardiff)
    MTE8
    MEET THE EXPERT 8
    Optogenetics: controlling cells with light
    14:45 - 15:30 
    MEET THE EXPERT 9
    All you need to know about CHIP-sequencing
    HALL D
    Chair: C McCabe (Birmingham)
    Expert: J Carroll (Cambridge)
    MTE9
    MEET THE EXPERT 9
    All you need to know about CHIP-sequencing
    15:45 - 16:15 
    TEA & COFFEE
    HALL Q
    16:15 - 16:45 
    AWARDS CEREMONY
    MAIN AUDITORIUM
    Chair: J Buckingham (London)
    17:15 - 17:45 
    SOCIETY FOR ENDOCRINOLOGY MEDAL LECTURE
    MAIN AUDITORIUM
    Chair: J Buckingham (London)
    PL7
    SOCIETY FOR ENDOCRINOLOGY MEDAL LECTURE
    Genetic, molecular and physiological mechanisms involved in human obesity
    18:00 - 18:45 
    BRITISH THYROID ASSOCIATION PITT-RIVERS LECTURE
    MAIN AUDITORIUM
    Chair: G Williams (London)
    PL6
    BRITISH THYROID ASSOCIATION PITT-RIVERS LECTURE
    The thyroid - too much and too little across the ages
    18:00 - 19:30 
    Otsuka satellite symposium
    Chair: P Bouloux (London)
    OS1
    Otsuka satellite symposium
    Hyponatraemia in neurosurgical patients: insights and implications
    OS2
    Otsuka satellite symposium
    Accelerating post-aneurysm recovery by correcting hypotraemia
    18:00 - 19:30 
    How do we balance a 21st century medicine with a 21st century economy?

    07:00 - 07:15 
    BREAKFAST
    QUEEN'S SUITE FOYER
    07:30 - 08:15 
    MEET THE EXPERT 6
    Prioritising therapy in neuroendocrine tumours
    SUPPORTED BY CLINICAL ENDOCRINOLOGY
    QUEEN'S SUITE A
    Chair: S Aylwin (London)
    Expert: C Toumpanakis (London)
    MTE6
    MEET THE EXPERT 6
    Prioritising therapy in neuroendocrine tumours
    07:30 - 08:15 
    MEET THE EXPERT 7
    Regulating periods and optimising fertility in PCOS
    SUPPORTED BY CLINICAL ENDOCRINOLOGY
    QUEEN'S SUITE B
    Chair: H Randeva (Warwick)
    Expert: C Duncan (Edinburgh)
    MTE7
    MEET THE EXPERT 7
    Regulating periods and optimising fertility in PCOS
    08:30 - 09:00 
    CLINICAL ENDOCRINOLOGY TRUST MEDAL LECTURE
    Developing growth hormone agonists and antagonists for the clinic
    SUPPORTED BY CLINICAL ENDOCRINOLOGY TRUST
    MAIN AUDITORIUM
    Chair: J Bevan (Aberdeen)
    PL8
    CLINICAL ENDOCRINOLOGY TRUST MEDAL LECTURE
    Developing growth hormone agonists and antagonists for the clinic
    09:00 - 09:30 
    CLINICAL ENDOCRINOLOGY TRUST VISITING PROFESSOR LECTURE
    Long-term outcome and quality of life in patients with disorders of sex development
    SUPPORTED BY CLINICAL ENDOCRINOLOGY TRUST
    MAIN AUDITORIUM
    Chair: J Connell (Dundee)
    PL9
    CLINICAL ENDOCRINOLOGY TRUST VISITING PROFESSOR LECTURE
    Long-term outcome and quality of life in patients with disorders of sex development
    Sao Paulo, Brazil
    09:30 - 10:00 
    Funding opportunities: NIHR/MRC Efficacy and Mechanisms Evaluations (EME) Board
    MAIN AUDITORIUM
    FO1.1
    Funding opportunities: NIHR/MRC Efficacy and Mechanisms Evaluations (EME) Board
    Opportunities in translational research - the NIHR/MRC Efficacy and Mechanisms Evaluations (EME) Board
    Oxford, United Kingdom
    FO1.2
    Funding opportunities: NIHR/MRC Efficacy and Mechanisms Evaluations (EME) Board
    NIHR research networks: an update

    Unknown speaker

    Liverpool, United Kingdom
    10:00 - 10:30 
    TEA & COFFEE
    HALL Q
    10:30 - 13:00 
    SENIOR ENDOCRINOLOGISTS' SESSION
    HALL D
    SE1.1
    SENIOR ENDOCRINOLOGISTS' SESSION
    Seeing the light
    SE1.2
    SENIOR ENDOCRINOLOGISTS' SESSION
    It's time to identify the hormone that maintains bodty fat content
    SE1.3
    SENIOR ENDOCRINOLOGISTS' SESSION
    UK stance on adult GH replacment maintains our isolation from Europe
    SE1.4
    SENIOR ENDOCRINOLOGISTS' SESSION
    Assisted conception and developing low cost version for the developing world
    SE1.5
    SENIOR ENDOCRINOLOGISTS' SESSION
    Tales from an arthritic endocrinologist - why does the endocrine dog not bark in the cytokine night?
    SE1.6
    SENIOR ENDOCRINOLOGISTS' SESSION
    Psychopathology of false conviction
    Montecastello di Vibio, Italy
    10:30 - 12:30 
    Clinical Management Workshop 3: ADVANCES IN ASSESSMENT AND MANAGEMENT OF INFERTILITY
    What the endocrinologist needs to know
    SUPPORTED BY CLINICAL ENDOCRINOLOGY
    QUEEN'S SUITE A
    Chairs: W Dhillo (London) & J George (Edinburgh)
    CM3.1
    Clinical Management Workshop 3: ADVANCES IN ASSESSMENT AND MANAGEMENT OF INFERTILITY
    Novel mutations causing infertility
    Lausanne, Switzerland
    CM3.2
    Clinical Management Workshop 3: ADVANCES IN ASSESSMENT AND MANAGEMENT OF INFERTILITY
    Semen analysis: what does it mean and can we improve it?
    CM3.3
    Clinical Management Workshop 3: ADVANCES IN ASSESSMENT AND MANAGEMENT OF INFERTILITY
    How can we predict ovarian reserve and how useful is this?
    Utrecht, The Netherlands
    CM3.4
    Clinical Management Workshop 3: ADVANCES IN ASSESSMENT AND MANAGEMENT OF INFERTILITY
    The endocrine basis of what we do in the IVF clinic
    10:30 - 12:30 
    Clinical Management Workshop 4: HOW DO I APPROACH...
    Real world approaches to clinical dilemmas
    SUPPORTED BY CLINICAL ENDOCRINOLOGY
    MAIN AUDITORIUM
    Chairs: J Bevan (Aberdeen) & A Paisley (Manchester)
    CM4.1
    Clinical Management Workshop 4: HOW DO I APPROACH...
    Drug-induced hyperprolactinaemia
    CM4.2
    Clinical Management Workshop 4: HOW DO I APPROACH...
    Endocrine assessment in HIV/AIDS
    CM4.3
    Clinical Management Workshop 4: HOW DO I APPROACH...
    Neuroendocrine assessment in morbid obesity

    Unknown speaker

    Liverpool, United Kingdom
    CM4.4
    Clinical Management Workshop 4: HOW DO I APPROACH...
    Endocrine evaluation in a patient with coeliac disease
    Newcastle, UK
    CM4.5
    Clinical Management Workshop 4: HOW DO I APPROACH...
    Hypogonadism in a man with cancer of the prostate
    CM4.6
    Clinical Management Workshop 4: HOW DO I APPROACH...
    Endocrine evaluation in a patient with iron overload
    Birmingham, UK
    12:30 - 13:15 
    MEET THE EXPERT 5 - REPEAT
    The surgical approaches to MEN1 - what the endocrinologist needs to know
    SUPPORTED BY CLINICAL ENDOCRINOLOGY
    MAIN AUDITORIUM
    Chair: S Ball (Newcastle)
    Expert: B Harrison (Sheffield)
    MTE5
    MEET THE EXPERT 5 - REPEAT
    The surgical approaches to MEN1 - what the endocrinologist needs to know
    Sheffield, UK
    12:30 - 13:15 
    MEET THE EXPERT 4 - REPEAT
    Management of persistent TSH elevation in hypothyroid patients
    SUPPORTED BY CLINICAL ENDOCRINOLOGY AND THE BRITISH THYROID FOUNDATION
    QUEEN'S SUITE B
    Chair: J Wass (Oxford)
    Expert: A Allahabadia (Sheffield)
    MTE4
    MEET THE EXPERT 4 - REPEAT
    Management of persistent TSH elevation in hypothyroid patients
    12:30 - 13:15 
    MEET THE EXPERT 3 - REPEAT
    Preventing and managing long term complications of acromegaly
    SUPPORTED BY CLINICAL ENDOCRINOLOGY
    QUEEN'S SUITE A
    Chair: R Murray (Leeds)
    Expert: K Meeran (London)
    MTE3
    MEET THE EXPERT 3 - REPEAT
    Preventing and managing long term complications of acromegaly
    13:15 - 14:00 
    MEET THE EXPERT 7 - REPEAT
    Regulating periods and optimising fertility in PCOS
    SUPPORTED BY CLINICAL ENDOCRINOLOGY
    QUEEN'S SUITE B
    Chair: H Randeva (Warwick)
    Expert: C Duncan (Edinburgh)
    MTE7
    MEET THE EXPERT 7 - REPEAT
    Regulating periods and optimising fertility in PCOS
    13:15 - 14:00 
    MEET THE EXPERT 6 - REPEAT
    SUPPORTED BY CLINICAL ENDOCRINOLOGY
    QUEEN'S SUITE A
    Chair: S Aylwin (London)
    Expert: C Toumpanakis (London)
    MTE6
    MEET THE EXPERT 6 - REPEAT
    Prioritising therapy in neuroendocrine tumours
Bo Abrahamsen
Holbæk, Denmark
Tue 20 09:15
CM2.3
Clinical Management Workshop 2: CONTROVERSIES IN AETIOLOGY AND MANAGEMENT OF OSTEOPOROSIS
Complications of antiresorptive agents

Unknown speaker

Holbæk, Denmark
R Ajjan
Wed 21 09:00
N1.1
Nurses' Session 1:
Thyroid Eye Disease - presentation and treatment
A Allahabadia
Wed 21 07:15
MTE4
MEET THE EXPERT 4
Management of persistent TSH elevation in hypothyroid patients
Thu 22 12:30
MTE4
MEET THE EXPERT 4 - REPEAT
Management of persistent TSH elevation in hypothyroid patients
R Allemann
Wed 21 13:45
MTE8
MEET THE EXPERT 8
Optogenetics: controlling cells with light
D Anderson
Montecastello di Vibio, Italy
Thu 22 12:35
SE1.6
SENIOR ENDOCRINOLOGISTS' SESSION
Psychopathology of false conviction
Montecastello di Vibio, Italy
J Arendt
Tue 20 14:30
S7.2
Symposium 7: LATITUDE: ENDOCRINE CONSEQUENCES OF HUMAN MIGRATION
Melatonin, light and sleep in the Antartic
W Arlt
Tue 20 07:15
MTE1
MEET THE EXPERT 1
Therapeutic management of adults with CAH
Tue 20 16:30
MTE1
MEET THE EXPERT 1 - REPEAT
Therapeutic management of adults with CAH
C Barratt
Thu 22 11:00
CM3.2
Clinical Management Workshop 3: ADVANCES IN ASSESSMENT AND MANAGEMENT OF INFERTILITY
Semen analysis: what does it mean and can we improve it?
R Bernhardt
Saarbrucken, Germany
Tue 20 08:45
S6.2
Symposium 6: INHIBITING STEROID ENZYMES TO TREAT COMMON DISEASE
Old drugs for new targets - CYP11B2 inhibitors for hypertension
Saarbrucken, Germany
Shalender Bhasin
Boston, USA
Mon 19 11:30
S3.2
Symposium 3: TESTOSTERONE IN MEN: HOW LOW CAN YOU GO?
Does testosterone treatment increase mortality in elderly men?
Boston, USA
N Bishop
Tue 20 08:45
CM2.2
Clinical Management Workshop 2: CONTROVERSIES IN AETIOLOGY AND MANAGEMENT OF OSTEOPOROSIS
Osteoporosis and metabolic bone disease in adolescence
P Bouloux
Mon 19 12:00
S3.3
Symposium 3: TESTOSTERONE IN MEN: HOW LOW CAN YOU GO?
What is the best form of testosterone replacement?
S Bouret
Los Angeles, USA
Wed 21 09:30
S9.2
Symposium 9: DEVELOPMENTAL PROGRAMMING OF ENDOCRINE DISEASE
Neuroendocrine origins of obesity
Los Angeles, USA
G Brabant
Mon 19 17:30
CM1.4
Clinical Management Workshop 1: THE LATE CONSEQUENCES OF CANCER THERAPY IN ADULTS
The late consequences of cancer therapy to the thyroid
F Broekmans
Utrecht, The Netherlands
Thu 22 11:30
CM3.3
Clinical Management Workshop 3: ADVANCES IN ASSESSMENT AND MANAGEMENT OF INFERTILITY
How can we predict ovarian reserve and how useful is this?
Utrecht, The Netherlands
M Bushall
Tue 20 16:30
S8.1
Symposium 8: SMALL MOLECULES, BIG EFFECTS: THE EMERGING ROLE FOR MICRO RNAS
MicroRNA: an introduction
J Carroll
Wed 21 14:45
MTE9
MEET THE EXPERT 9
All you need to know about CHIP-sequencing
A Clow
Tue 20 15:00
S7.3
Symposium 7: LATITUDE: ENDOCRINE CONSEQUENCES OF HUMAN MIGRATION
Cortisol and mood - coping with seasons
M Cnop
Brussels, Belgium
Mon 19 12:00
S2.3
Symposium 2: ENDOPLASMIC RETICULUM STRESS IN METABOLIC DISEASE AND OBESITY
Lipotoxic endoplasmic reticulum stress and pancreatic beta-cell demise in type 2 diabetes
Brussels, Belgium
J Connell
Wed 21 15:15
S11.4
Symposium 11: NOVEL LESSONS FROM MINERALOCORTICOID EXCESS
Therapeutic options for mineralocorticoid hypertension
B Cooke
Thu 22 10:30
SE1.1
SENIOR ENDOCRINOLOGISTS' SESSION
Seeing the light
I Cooke
Thu 22 11:45
SE1.4
SENIOR ENDOCRINOLOGISTS' SESSION
Assisted conception and developing low cost version for the developing world
M Cooper
Tue 20 08:15
S6.1
Symposium 6: INHIBITING STEROID ENZYMES TO TREAT COMMON DISEASE
Ageing gracefully - the role of 11beta-HSD1
P Dahia
San Antonio, USA
Wed 21 09:30
S10.2
Symposium 10:
Molecular mechanisms of phaeochromocytoma and tumorigenesis
San Antonio, USA
H Dawson-Smith
Wed 21 15:15
N2.5
Nurses' Session 2:
Living with Addison's
S Driesche
Tue 20 15:00
OC4.5
Oral Communications 4: Steroids
A novel repressor mechanism regulating fetal Leydig cell steroidogenesis, pertubation of which results in masculinization disorders
C Duncan
Thu 22 07:30
MTE7
MEET THE EXPERT 7
Regulating periods and optimising fertility in PCOS
Thu 22 13:15
MTE7
MEET THE EXPERT 7 - REPEAT
Regulating periods and optimising fertility in PCOS
R Eastell
Tue 20 09:45
CM2.4
Clinical Management Workshop 2: CONTROVERSIES IN AETIOLOGY AND MANAGEMENT OF OSTEOPOROSIS
New and emerging therapies for osteoporosis
C Edwards
Thu 22 12:10
SE1.5
SENIOR ENDOCRINOLOGISTS' SESSION
Tales from an arthritic endocrinologist - why does the endocrine dog not bark in the cytokine night?
S Farooqi
Wed 21 17:15
PL7
SOCIETY FOR ENDOCRINOLOGY MEDAL LECTURE
Genetic, molecular and physiological mechanisms involved in human obesity
F Farrokhnia
Mon 19 17:15
OC2.6
Oral Communications 2: REPRODUCTION AND BONE
Identification of microRNAs involved in regulating growth factor signalling in the first trimester placenta
Karen Forbes
Leeds, UK
Tue 20 14:00
YE1.1
Young Endocrinologists' Symposium: OBTAINING FUNDING AND NETWORKING FOR YOUNG ENDOCRINOLOGISTS
Obtaining fellowship funding and networking
Leeds, UK
Tue 20 17:00
S8.2
Symposium 8: SMALL MOLECULES, BIG EFFECTS: THE EMERGING ROLE FOR MICRO RNAS
MicroRNA regulation of the IGF axis
Leeds, UK
S Ford
Laramie, USA
Wed 21 10:30
S9.4
Symposium 9: DEVELOPMENTAL PROGRAMMING OF ENDOCRINE DISEASE
Obesity in pregnancy: implications for the next generation
Laramie, USA
P Foster
Tue 20 09:15
S6.3
Symposium 6: INHIBITING STEROID ENZYMES TO TREAT COMMON DISEASE
Dual aromatase and steroid sulfatase inhibition in breast cancer
R Fowkes
Tue 20 15:30
YE1.4
Young Endocrinologists' Symposium: OBTAINING FUNDING AND NETWORKING FOR YOUNG ENDOCRINOLOGISTS
Trials and tribulations of the university lecturer
J Franklyn
Wed 21 16:45
PL6
BRITISH THYROID ASSOCIATION PITT-RIVERS LECTURE
The thyroid - too much and too little across the ages
L Gathercole
Mon 19 18:10
YEP1.1
YOUNG ENDOCRINOLOGISTS' PRIZE LECTURES
Challenging the dogma: Tissue specific regulation of insulin action
J George
Mon 19 13:30
OC1.1
Oral Communications 1: YOUNG ENDOCRINOLOGISTS' PRIZE SESSION
Functional characterisation and translational clinical applications of kisspeptin-10
A Gogakos
Mon 19 14:00
OC1.3
Oral Communications 1: YOUNG ENDOCRINOLOGISTS' PRIZE SESSION
Effect of selenium status on the skeleton in post-menopausal women: the OPUS study
D Greenfield
Mon 19 16:00
CM1.1
Clinical Management Workshop 1: THE LATE CONSEQUENCES OF CANCER THERAPY IN ADULTS
The follow up of cancer survivors
F Hannan
Mon 19 13:45
OC1.2
Oral Communications 1: YOUNG ENDOCRINOLOGISTS' PRIZE SESSION
Structure-function analysis of calcium-sensing receptor (CaSR) mutations reveal clustering at calcium binding sites of the extracellular bilobed venus flytrap domain
Mon 19 17:45
OC2.8
Oral Communications 2: REPRODUCTION AND BONE
A calcium-sensing receptor (CaSR) variant, Glu250Lys, present in familial hypocalciuric hypercalcaemia (FHH) and autosomal dominant hypocalcaemic hypercalciuria (ADHH) probands represents a functionally neutral polymorphism: lessons for CaSR mutational analysis
D Hanson
Tue 20 16:30
OC5.1
Oral Communications 5: GROWTH, TUMOURS AND PITUITARY
Human growth is regulated by an ubiquitination pathway including CUL7, OBSL1 and CCDC8
B Harrison
Sheffield, UK
Wed 21 07:15
MTE5
MEET THE EXPERT 5
The surgical approaches to MEN1 - what the endocrinologist needs to know
Sheffield, UK
Thu 22 12:30
MTE5
MEET THE EXPERT 5 - REPEAT
The surgical approaches to MEN1 - what the endocrinologist needs to know
Sheffield, UK
A Harte
Tue 20 08:30
OC3.2
Oral Communications 3: OBESITY, THYROID AND ADDISON'S DISEASE
Post-prandial high fat intake leads to acute exposure to circulating endotoxin in type 2 diabetes mellitus subjects
A Hattersley
Mon 19 12:30
S2.4
Symposium 2: ENDOPLASMIC RETICULUM STRESS IN METABOLIC DISEASE AND OBESITY
Patients with monogenic diabetes resulting from ER stress of the pancreatic beta-cell
I Hay
Rochester, USA
Mon 19 14:30
S4.3
Symposium 4: ADVANCES IN THE MANAGEMENT OF DIFFERENTIATED THYROID CANCER
The place of radioiodine in the management of thyroid cancer
Rochester, USA
J Hazlehurst
Tue 20 15:30
OC4.7
Oral Communications 4: Steroids
Glucocorticoids increase subcutaneous adipose tissue insulin sensitivity in vivo: a randomised double-blind, placebo controlled, cross over study
G Hervey
Thu 22 10:55
SE1.2
SENIOR ENDOCRINOLOGISTS' SESSION
It's time to identify the hormone that maintains bodty fat content
M Holmes
Wed 21 10:00
S9.3
Symposium 9: DEVELOPMENTAL PROGRAMMING OF ENDOCRINE DISEASE
The foetus or the placenta? Targets of glucorticoid programming
T Howlett
Tue 20 18:15
OC5.8
Oral Communications 5: GROWTH, TUMOURS AND PITUITARY
Control of GH and IGF1 in acromegaly in the UK: responses to medical treatment
Wed 21 14:30
N2.3
Nurses' Session 2:
Introduction to Addison's
J Idkowiak
Tue 20 14:45
OC4.4
Oral Communications 4: Steroids
Broad phenotypic spectrum of 17a-hydroxylase deficiency: functional characterisation of 4 novel mutations in the CYP17A1 gene
P Igaz
Tue 20 18:00
S8.4
Symposium 8: SMALL MOLECULES, BIG EFFECTS: THE EMERGING ROLE FOR MICRO RNAS
MicroRNA in the diagnosis and therapy of endcorine cancers
M Jangani
Mon 19 15:15
OC1.8
Oral Communications 1: YOUNG ENDOCRINOLOGISTS' PRIZE SESSION
Metastasis related methyltransferase 1 (Merm1)/WBSCR22 regulates glucocorticoid receptor (GR) function
C Jayasena
Mon 19 16:15
OC2.2
Oral Communications 2: REPRODUCTION AND BONE
Contrasting effects of kisspeptin-10 between men and women reveal sexual dimorphism in the hypothalamic regulation of human reproduction
H Jones
Thu 22 11:50
CM4.5
Clinical Management Workshop 4: HOW DO I APPROACH...
Hypogonadism in a man with cancer of the prostate
J Juul-Holst
Copenhagen, Denmark
Wed 21 11:30
PL4
SOCIETY FOR ENDOCRINOLOGY EUROPEAN MEDAL LECTURE
GLP-1 therapy of type 2 diabetes - current status
Copenhagen, Denmark
G Karsenty
New York, USA
Tue 20 11:20
PL2
SOCIETY FOR ENDOCRINOLOGY HOFFENBERG INTERNATIONAL MEDAL LECTURE
Bone as endocrine organ
New York, USA
T Kearney
Thu 22 10:30
CM4.1
Clinical Management Workshop 4: HOW DO I APPROACH...
Drug-induced hyperprolactinaemia
D Kendall
Tue 20 08:15
OC3.1
Oral Communications 3: OBESITY, THYROID AND ADDISON'S DISEASE
Metformin in obese children and adolescents (MOCA) trial
J Kirk
Birmingham, UK
Thu 22 12:10
CM4.6
Clinical Management Workshop 4: HOW DO I APPROACH...
Endocrine evaluation in a patient with iron overload
Birmingham, UK
Dr Kenneth  Korach
Durham, USA
Tue 20 10:40
PL1
SOCIETY FOR ENDOCRINOLOGY DALE MEDAL LECTURE
Estrogen receptor insensitivity: physiological and clinical consequences
Durham, USA
Professor Márta Korbonits
London, UK
Mon 19 12:30
S1.4
Symposium 1: GENETIC REGULATION OF PITUITARY TUMOURIGENESIS
Molecular signatures of pituitary tumours

Unknown speaker

London, UK
J Kowalczyk
Mon 19 14:45
OC1.6
Oral Communications 1: YOUNG ENDOCRINOLOGISTS' PRIZE SESSION
A homozygous glutathione peroxidase 1 mutation, p.Arg130-Leu133del, in a patient with familial glucocorticoid deficiency
T Kurzawinski
Wed 21 14:45
S12.3
Symposium 12: MEDULLARY THYROID CANCER
The diagnosis and management of MTC
G Lanza
St Louis, USA
Mon 19 14:10
AP1.2
Applied Physiology Workshop:
Nanoparticles as imaging agents
St Louis, USA
V Leite
Lisbon, Portugal
Wed 21 14:15
S12.2
Symposium 12: MEDULLARY THYROID CANCER
RAS mutations in sporadic MTC
Lisbon, Portugal
N-A Liu
Los Angeles, USA
Mon 19 11:30
S1.2
Symposium 1: GENETIC REGULATION OF PITUITARY TUMOURIGENESIS
Modelling pituitary tumours in zebrafish
Los Angeles, USA
A Madathil
Tue 20 09:45
OC3.7
Oral Communications 3: OBESITY, THYROID AND ADDISON'S DISEASE
Subclinical hypothyroidism is associated with fatigue and impaired functional status in males in the Whickham 20-year follow up cohort
E Maher
Wed 21 09:00
S10.1
Symposium 10:
Genetics and epidemiology
H Mani
Mon 19 17:30
OC2.7
Oral Communications 2: REPRODUCTION AND BONE
Increased cardiovascular events in women with polycystic ovary syndrome: retrospective analysis of a large database
V Marion
Strasbourg, France
Tue 20 09:00
OC3.4
Oral Communications 3: OBESITY, THYROID AND ADDISON'S DISEASE
Glucose absorption capacity of the mature adipose tissue is increased after Bardet-Biedl syndrome induced ciliary defect in adipocytes' precursors
Strasbourg, France
J Martinez-Barbera
Mon 19 12:00
S1.3
Symposium 1: GENETIC REGULATION OF PITUITARY TUMOURIGENESIS
Mouse model of craniopharyngioma
K McInnes
Tue 20 15:15
OC4.6
Oral Communications 4: Steroids
Fatty liver in a mouse model of congenital adrenal hyperplasia is driven by peroxisome proliferator-activated receptors
J McLaren
Wed 21 10:30
N1.3
Nurses' Session 1:
Thyroid Eye Disease
K Meeran
Tue 20 07:15
MTE3
MEET THE EXPERT 3
Preventing and managing long term complications of acromegaly
Thu 22 12:30
MTE3
MEET THE EXPERT 3 - REPEAT
Preventing and managing long term complications of acromegaly
B Mendoca
Sao Paulo, Brazil
Thu 22 09:00
PL9
CLINICAL ENDOCRINOLOGY TRUST VISITING PROFESSOR LECTURE
Long-term outcome and quality of life in patients with disorders of sex development
Sao Paulo, Brazil
N Milton
Mon 19 16:30
OC2.3
Oral Communications 2: REPRODUCTION AND BONE
Kissorphin, a hexapeptide derivative of kisspeptin, acts via neuropeptide FF receptors to inhibit cyclic adenosine monophosphate release but has no gonadotrophin-releasing hormone releasing activity
S Mirczuk
Tue 20 17:45
OC5.6
Oral Communications 5: GROWTH, TUMOURS AND PITUITARY
SUMOylation genes in pituitary gonadotrophs: wrestling with GnRH signalling
A Mitchell
Tue 20 09:30
OC3.6
Oral Communications 3: OBESITY, THYROID AND ADDISON'S DISEASE
GATA3 polymorphisms are associated with autoimmune Addison's disease
C Moran
Cambridge
Mon 19 14:15
OC1.4
Oral Communications 1: YOUNG ENDOCRINOLOGISTS' PRIZE SESSION
The thyroid hormone receptor-coactivator interface mediates negative feedback regulation of the human pituitary-thyroid axis
Cambridge
C Morgan
Tue 20 08:45
OC3.3
Oral Communications 3: OBESITY, THYROID AND ADDISON'S DISEASE
Risk of diabetes, cancer, large vessel disease and mortality in young women with polycystic ovary syndrome: a retrospective databased analysis
S Morgan
Tue 20 14:15
OC4.2
Oral Communications 4: Steroids
Age-dependent increase in the expression/activity of 11β-HSD1 in key metabolic tissues may underpin the ageing phenotype, notably sarcopenia
M Morris
Wed 21 10:00
N1.2
Nurses' Session 1:
Thyroid Eye Disease
Z Mughal
Manchester, UK
Tue 20 15:30
S7.4
Symposium 7: LATITUDE: ENDOCRINE CONSEQUENCES OF HUMAN MIGRATION
Resurgence of vitamin D deficiency rickets in the UK
Manchester, UK
S Myint
Wed 21 13:45
N2.1
Nurses' Session 2:
Conn's and phaeochromocytoma
R Nadif
Mon 19 17:00
OC2.5
Oral Communications 2: REPRODUCTION AND BONE
Nutrient regulation of growth factor signalling in human placenta
K Newbold
Mon 19 15:00
S4.4
Symposium 4: ADVANCES IN THE MANAGEMENT OF DIFFERENTIATED THYROID CANCER
Novel treatments - from PCR to patient
S Ozanne
Wed 21 09:00
S9.1
Symposium 9: DEVELOPMENTAL PROGRAMMING OF ENDOCRINE DISEASE
Developmental programming of type 2 diabetes
U Ozcan
Boston, USA
Mon 19 11:30
S2.2
Symposium 2: ENDOPLASMIC RETICULUM STRESS IN METABOLIC DISEASE AND OBESITY
ER stress, leptin signalling and obesity
Boston, USA
S Parajes
Mon 19 15:00
OC1.7
Oral Communications 1: YOUNG ENDOCRINOLOGISTS' PRIZE SESSION
Progressive adrenal insufficiency and 46,XY DSD caused by two novel mutations in the cytochrome P450 side-chain cleavage (CYP11A1) gene
S Pearce
Newcastle, UK
Tue 20 09:15
OC3.5
Oral Communications 3: OBESITY, THYROID AND ADDISON'S DISEASE
Steroidogenic function following B lymphocyte depletion therapy in new onset autoimmune Addison's disease
Newcastle, UK
Thu 22 11:30
CM4.4
Clinical Management Workshop 4: HOW DO I APPROACH...
Endocrine evaluation in a patient with coeliac disease
Newcastle, UK
B Pedersen
Copenhagen, Denmark
Mon 19 16:00
S5.1
Symposium 5: SPRINT OR MARATHON? MUSCLING IN ON THE OLYMPICS
Muscles and their myokines
Copenhagen, Denmark
N Peel
Tue 20 08:15
CM2.1
Clinical Management Workshop 2: CONTROVERSIES IN AETIOLOGY AND MANAGEMENT OF OSTEOPOROSIS
Impact of lifestyle choices on skeletal health
J Pickup
Mon 19 14:50
AP1.3
Applied Physiology Workshop:
Nanomedicine in clinical diabetes
D Pinato
Tue 20 17:30
OC5.5
Oral Communications 5: GROWTH, TUMOURS AND PITUITARY
Role of the hypoxic signalling pathways in the histopathological prediction of malignancy in phaeochromocytomas and paragangliomas
Nelly Pitteloud
Lausanne, Switzerland
Thu 22 10:30
CM3.1
Clinical Management Workshop 3: ADVANCES IN ASSESSMENT AND MANAGEMENT OF INFERTILITY
Novel mutations causing infertility
Lausanne, Switzerland
P-F Plouin
Paris, France
Wed 21 10:30
S10.4
Symposium 10:
Novel therapies for malignant phaeochromocytomas and paragangliomas
Paris, France
M Poy
Berlin, Germany
Tue 20 17:30
S8.3
Symposium 8: SMALL MOLECULES, BIG EFFECTS: THE EMERGING ROLE FOR MICRO RNAS
MicroRNA and the beta-cell
Berlin, Germany
S Rahman
Mon 19 17:30
S5.4
Symposium 5: SPRINT OR MARATHON? MUSCLING IN ON THE OLYMPICS
Mitochondrial dysfunction and muscle disease
T Raivio
Helsinki, Finland
Mon 19 12:30
S3.4
Symposium 3: TESTOSTERONE IN MEN: HOW LOW CAN YOU GO?
Can testosterone therapy be stopped in some hypogonadal patients?
Helsinki, Finland
M Read
Tue 20 10:00
OC3.8
Oral Communications 3: OBESITY, THYROID AND ADDISON'S DISEASE
Dietary factors augment the ability of the proto-oncogene PBF to induce goitrogenesis and hyperplasia in vivo
M Reincke
Wed 21 14:45
S11.3
Symposium 11: NOVEL LESSONS FROM MINERALOCORTICOID EXCESS
Long term consequences of primary hyperaldosteronism
P Richards
Mon 19 13:30
S4.1
Symposium 4: ADVANCES IN THE MANAGEMENT OF DIFFERENTIATED THYROID CANCER
Can imaging predict malignancy in a thyroid nodule?
D Ron
Mon 19 11:00
S2.1
Symposium 2: ENDOPLASMIC RETICULUM STRESS IN METABOLIC DISEASE AND OBESITY
ER stress and metabolic regulation
R Ross
Thu 22 08:30
PL8
CLINICAL ENDOCRINOLOGY TRUST MEDAL LECTURE
Developing growth hormone agonists and antagonists for the clinic
M Sadeq
Tue 20 15:45
OC4.8
Oral Communications 4: Steroids
The role of a novel co-regulator in modifying the transcriptional activities of the glucocorticoid receptor
K Sakamoto
Mon 19 17:00
S5.3
Symposium 5: SPRINT OR MARATHON? MUSCLING IN ON THE OLYMPICS
Novel signalling mechanisms controlling glycogen homeostasis in muscle
J Saleh
Tue 20 18:00
OC5.7
Oral Communications 5: GROWTH, TUMOURS AND PITUITARY
The role of the familialpituitary adenoma gene, AIP, in the proliferative and invasive activity of a malignant pancreatic cell line
M Santoro
Naples, Italy
Wed 21 13:45
S12.1
Symposium 12: MEDULLARY THYROID CANCER
Molecular pathogenesis of MTC
Naples, Italy
P Sassone-Corsi
Irvine, USA
Tue 20 18:40
PL3
SOCIETY FOR ENDOCRINOLOGY TRANSATLANTIC MEDAL
Metabolism to epigenetics: the circadian clock link
Irvine, USA
M Schlumberger
Paris, France
Wed 21 15:15
S12.4
Symposium 12: MEDULLARY THYROID CANCER
Novel targeted therapies for MTC
Paris, France
N Schoenmakers
Mon 19 14:30
OC1.5
Oral Communications 1: YOUNG ENDOCRINOLOGISTS' PRIZE SESSION
Growth retardation and severe constipation due to the first human, dominant negative thyroid hormone receptor alpha mutation
S Shalet
Thu 22 11:20
SE1.3
SENIOR ENDOCRINOLOGISTS' SESSION
UK stance on adult GH replacment maintains our isolation from Europe
M Sheppard
Wed 21 12:00
PL5
SOCIETY FOR ENDOCRINOLOGY JUBILEE MEDAL LECTURE
Acromegaly - improving outcomes
P Southern
Mon 19 13:30
AP1.1
Applied Physiology Workshop:
Magnetic nanoparticles for drug delivery
T Stephenson
Mon 19 14:00
S4.2
Symposium 4: ADVANCES IN THE MANAGEMENT OF DIFFERENTIATED THYROID CANCER
Predictive value of cytology and molecular markers in thyroid cancer
A Stevens
Tue 20 16:45
OC5.2
Oral Communications 5: GROWTH, TUMOURS AND PITUITARY
A network analysis of gene expression through childhood highlights changes related to age and growth
Professor Roland Stimson
Edinburgh, UK
Mon 19 18:40
YEP1.2
YOUNG ENDOCRINOLOGISTS' PRIZE LECTURES
Quantifying in vivo extra-adrenal cortisol production and dysregulation in human metabolic disease
Edinburgh, UK
C Sze
Tue 20 17:00
OC5.3
Oral Communications 5: GROWTH, TUMOURS AND PITUITARY
Long term experience of 131I-MIBG therapy in the treatment of neuroendocrine tumours: has it improved survival and what are the long term sequelae?
Dr Abd Tahrani
Birmingham, UK
Tue 20 14:30
YE1.2
Young Endocrinologists' Symposium: OBTAINING FUNDING AND NETWORKING FOR YOUNG ENDOCRINOLOGISTS
Pathways in clinical academia, fellowships and networking
Birmingham, UK
A Taylor
Tue 20 17:15
OC5.4
Oral Communications 5: GROWTH, TUMOURS AND PITUITARY
Steroid metabolomics in adrenocortical carcinoma reveal mitotane as an inducer of CYP3A4 and an inhibitor of 5alpha-reductase activity with major implications for drug metabolism and hydrocortisone replacement
Raj Thakker
Oxford, United Kingdom
Mon 19 11:00
S1.1
Symposium 1: GENETIC REGULATION OF PITUITARY TUMOURIGENESIS
Genetic models of pituitary disease in MEN1
Oxford, United Kingdom
Thu 22 09:30
FO1.1
Funding opportunities: NIHR/MRC Efficacy and Mechanisms Evaluations (EME) Board
Opportunities in translational research - the NIHR/MRC Efficacy and Mechanisms Evaluations (EME) Board
Oxford, United Kingdom
M Thomas
Tue 20 14:00
S7.1
Symposium 7: LATITUDE: ENDOCRINE CONSEQUENCES OF HUMAN MIGRATION
The origins and evolution of lactase persistence
I Thompson
Tue 20 15:00
YE1.3
Young Endocrinologists' Symposium: OBTAINING FUNDING AND NETWORKING FOR YOUNG ENDOCRINOLOGISTS
Career opportunities in the States
V Thornton-Jones
Wed 21 15:00
N2.4
Nurses' Session 2:
Day-to-day practice on management of steroid replacement
Ana Tiganescu
Leeds, United Kingdom
Tue 20 14:00
OC4.1
Oral Communications 4: Steroids
Increased 11β-hydroxysteroid dehydrogenase type 1 activity is associated with the adverse expression of glucocorticoid target genes in ageing human skin

Unknown speaker

Leeds, United Kingdom
H Timmers
Nijmegen, The Netherlands
Wed 21 10:00
S10.3
Symposium 10:
Laboratory assessment and diagnostic imaging
Nijmegen, The Netherlands
A Toogood
Mon 19 16:30
CM1.2
Clinical Management Workshop 1: THE LATE CONSEQUENCES OF CANCER THERAPY IN ADULTS
The impact of cancer treatment on pituitary function
C Toumpanakis
Thu 22 07:30
MTE6
MEET THE EXPERT 6
Prioritising therapy in neuroendocrine tumours
Thu 22 13:15
MTE6
MEET THE EXPERT 6 - REPEAT
Prioritising therapy in neuroendocrine tumours
G Trew
Thu 22 12:30
CM3.4
Clinical Management Workshop 3: ADVANCES IN ASSESSMENT AND MANAGEMENT OF INFERTILITY
The endocrine basis of what we do in the IVF clinic
M Vanderpump
Tue 20 07:15
MTE2
MEET THE EXPERT 2
Amiodarone
Tue 20 17:15
MTE2
MEET THE EXPERT 2 - REPEAT
Amiodarone
S Vohra
Mon 19 16:45
OC2.4
Oral Communications 2: REPRODUCTION AND BONE
ERβ and GPR30 mediate distinct and opposite oestrogenic influences on microglial phagocytosis of apoptotic neuronal cells
A Wagenmakers
Mon 19 16:30
S5.2
Symposium 5: SPRINT OR MARATHON? MUSCLING IN ON THE OLYMPICS
Exercise effects on fat metabolism and insulin sensitivity in human muscle
H Wallace
Mon 19 17:00
CM1.3
Clinical Management Workshop 1: THE LATE CONSEQUENCES OF CANCER THERAPY IN ADULTS
The impact of cancer treatment on fertility and pregnancy
R Warth
Regensburg, Germany
Wed 21 13:45
S11.1
Symposium 11: NOVEL LESSONS FROM MINERALOCORTICOID EXCESS
A difficult TASK: murine models of mineralocorticoid excess
Regensburg, Germany
John Wilding
Liverpool, United Kingdom
Thu 22 09:45
FO1.2
Funding opportunities: NIHR/MRC Efficacy and Mechanisms Evaluations (EME) Board
NIHR research networks: an update

Unknown speaker

Liverpool, United Kingdom
Thu 22 11:10
CM4.3
Clinical Management Workshop 4: HOW DO I APPROACH...
Neuroendocrine assessment in morbid obesity

Unknown speaker

Liverpool, United Kingdom
P Williams
Mon 19 16:00
OC2.1
Oral Communications 2: REPRODUCTION AND BONE
The expression of kisspeptin and kisspeptin receptor is altered in pre-eclampsia
E Wilson
Chapel Hill, USA
Tue 20 09:45
S6.4
Symposium 6: INHIBITING STEROID ENZYMES TO TREAT COMMON DISEASE
Potential prostate cancer drug target: bioactivation of androstanediol by conversion to dihydrotestosterone
Chapel Hill, USA
A Wren
Thu 22 10:50
CM4.2
Clinical Management Workshop 4: HOW DO I APPROACH...
Endocrine assessment in HIV/AIDS
F Wu
Mon 19 11:00
S3.1
Symposium 3: TESTOSTERONE IN MEN: HOW LOW CAN YOU GO?
Is there a male menopause - lesson from the European Male Ageing Study
P Yeoh
Wed 21 14:15
N2.2
Nurses' Session 2:
Nursing case study on phaeochromocytoma
M Zennaro
Paris, France
Wed 21 14:15
S11.2
Symposium 11: NOVEL LESSONS FROM MINERALOCORTICOID EXCESS
Human potassium channel mutations and mineralocorticoid hypertension
Paris, France
A Zielinska
Tue 20 14:30
OC4.3
Oral Communications 4: Steroids
A hypomorphic H6PD allele is sufficient to rescue the skeletal myopathy but not the lack of 11β-HSd type-1 mediated glucocorticoid regeneration phenotypes of H6PDKO mice
Workshop 0
Oral 0
Expert 0
Plenary 0
Catering and Social 0
Nurse 0
Other 0
Symposium 0
No Session Type 75
Mon 19 11:00
Symposium 1: GENETIC REGULATION OF PITUITARY TUMOURIGENESIS
DEVELOPED WITH THE SOCIETY FOR ENDOCRINOLOGY'S PITUITARY SPECIAL INTEREST GROUP AND THE ASSOCIATION FOR MULTIPLE ENDOCRINE NEOPLASIA DISORDERS
QUEEN'S SUITE A
Chairs: R Fowkes (London) & H Chahal (London)
Mon 19 11:00
S1.1
Symposium 1: GENETIC REGULATION OF PITUITARY TUMOURIGENESIS
Genetic models of pituitary disease in MEN1
Oxford, United Kingdom
Mon 19 11:30
S1.2
Symposium 1: GENETIC REGULATION OF PITUITARY TUMOURIGENESIS
Modelling pituitary tumours in zebrafish
Los Angeles, USA
Mon 19 12:00
S1.3
Symposium 1: GENETIC REGULATION OF PITUITARY TUMOURIGENESIS
Mouse model of craniopharyngioma
Mon 19 12:30
S1.4
Symposium 1: GENETIC REGULATION OF PITUITARY TUMOURIGENESIS
Molecular signatures of pituitary tumours

Unknown speaker

London, UK
Mon 19 11:00
Symposium 2: ENDOPLASMIC RETICULUM STRESS IN METABOLIC DISEASE AND OBESITY
Stress caused by unfolded and misfolded proteins in the endoplasmic reticulum (so called "ER stress") intersects with metabolic disease at multiple levels
QUEEN'S SUITE B
Chairs: P Chapple (London) & E Harno (Manchester)
Mon 19 11:00
S2.1
Symposium 2: ENDOPLASMIC RETICULUM STRESS IN METABOLIC DISEASE AND OBESITY
ER stress and metabolic regulation
Mon 19 11:30
S2.2
Symposium 2: ENDOPLASMIC RETICULUM STRESS IN METABOLIC DISEASE AND OBESITY
ER stress, leptin signalling and obesity
Boston, USA
Mon 19 12:00
S2.3
Symposium 2: ENDOPLASMIC RETICULUM STRESS IN METABOLIC DISEASE AND OBESITY
Lipotoxic endoplasmic reticulum stress and pancreatic beta-cell demise in type 2 diabetes
Brussels, Belgium
Mon 19 12:30
S2.4
Symposium 2: ENDOPLASMIC RETICULUM STRESS IN METABOLIC DISEASE AND OBESITY
Patients with monogenic diabetes resulting from ER stress of the pancreatic beta-cell
Mon 19 11:00
Symposium 3: TESTOSTERONE IN MEN: HOW LOW CAN YOU GO?
DEVELOPED WITH THE SOCIETY FOR ENDOCRINOLOGY'S ANDROLOGY SPECIAL INTEREST GROUP AND THE KLINEFELTER'S SYNDROME ASSOCIATION
MAIN AUDITORIUM
Chairs: R Quinton (Newcastle) & A Theodoraki (London)
Mon 19 11:00
S3.1
Symposium 3: TESTOSTERONE IN MEN: HOW LOW CAN YOU GO?
Is there a male menopause - lesson from the European Male Ageing Study
Mon 19 11:30
S3.2
Symposium 3: TESTOSTERONE IN MEN: HOW LOW CAN YOU GO?
Does testosterone treatment increase mortality in elderly men?
Boston, USA
Mon 19 12:00
S3.3
Symposium 3: TESTOSTERONE IN MEN: HOW LOW CAN YOU GO?
What is the best form of testosterone replacement?
Mon 19 12:30
S3.4
Symposium 3: TESTOSTERONE IN MEN: HOW LOW CAN YOU GO?
Can testosterone therapy be stopped in some hypogonadal patients?
Helsinki, Finland
Mon 19 13:00
LUNCH
HALL Q
Mon 19 13:30
Applied Physiology Workshop:
NANOMEDICINE
QUEEN'S SUITE B
Chairs: M Gurnell (Cambridge) & R Fowkes (London)
Mon 19 13:30
AP1.1
Applied Physiology Workshop:
Magnetic nanoparticles for drug delivery
Mon 19 14:10
AP1.2
Applied Physiology Workshop:
Nanoparticles as imaging agents
St Louis, USA
Mon 19 14:50
AP1.3
Applied Physiology Workshop:
Nanomedicine in clinical diabetes
Mon 19 13:30
Oral Communications 1: YOUNG ENDOCRINOLOGISTS' PRIZE SESSION
QUEEN'S SUITE A
Chairs: G Karsenty (New York, NY, USA) & J Newell-Price (Sheffield)
Mon 19 13:30
OC1.1
Oral Communications 1: YOUNG ENDOCRINOLOGISTS' PRIZE SESSION
Functional characterisation and translational clinical applications of kisspeptin-10
Mon 19 13:45
OC1.2
Oral Communications 1: YOUNG ENDOCRINOLOGISTS' PRIZE SESSION
Structure-function analysis of calcium-sensing receptor (CaSR) mutations reveal clustering at calcium binding sites of the extracellular bilobed venus flytrap domain
Mon 19 14:00
OC1.3
Oral Communications 1: YOUNG ENDOCRINOLOGISTS' PRIZE SESSION
Effect of selenium status on the skeleton in post-menopausal women: the OPUS study
Mon 19 14:15
OC1.4
Oral Communications 1: YOUNG ENDOCRINOLOGISTS' PRIZE SESSION
The thyroid hormone receptor-coactivator interface mediates negative feedback regulation of the human pituitary-thyroid axis
Cambridge
Mon 19 14:30
OC1.5
Oral Communications 1: YOUNG ENDOCRINOLOGISTS' PRIZE SESSION
Growth retardation and severe constipation due to the first human, dominant negative thyroid hormone receptor alpha mutation
Mon 19 14:45
OC1.6
Oral Communications 1: YOUNG ENDOCRINOLOGISTS' PRIZE SESSION
A homozygous glutathione peroxidase 1 mutation, p.Arg130-Leu133del, in a patient with familial glucocorticoid deficiency
Mon 19 15:00
OC1.7
Oral Communications 1: YOUNG ENDOCRINOLOGISTS' PRIZE SESSION
Progressive adrenal insufficiency and 46,XY DSD caused by two novel mutations in the cytochrome P450 side-chain cleavage (CYP11A1) gene
Mon 19 15:15
OC1.8
Oral Communications 1: YOUNG ENDOCRINOLOGISTS' PRIZE SESSION
Metastasis related methyltransferase 1 (Merm1)/WBSCR22 regulates glucocorticoid receptor (GR) function
Mon 19 13:30
Symposium 4: ADVANCES IN THE MANAGEMENT OF DIFFERENTIATED THYROID CANCER
Thyroid cancer management is evolving to reflect novel developments in imaging, cytology, molecular biology and the outcome of trials evaluating low versus high dose radioiodine therapy
MAIN AUDITORIUM
Chairs: K Boelaert (Birmingham) & P Newey (Oxford)
Mon 19 13:30
S4.1
Symposium 4: ADVANCES IN THE MANAGEMENT OF DIFFERENTIATED THYROID CANCER
Can imaging predict malignancy in a thyroid nodule?
Mon 19 14:00
S4.2
Symposium 4: ADVANCES IN THE MANAGEMENT OF DIFFERENTIATED THYROID CANCER
Predictive value of cytology and molecular markers in thyroid cancer
Mon 19 14:30
S4.3
Symposium 4: ADVANCES IN THE MANAGEMENT OF DIFFERENTIATED THYROID CANCER
The place of radioiodine in the management of thyroid cancer
Rochester, USA
Mon 19 15:00
S4.4
Symposium 4: ADVANCES IN THE MANAGEMENT OF DIFFERENTIATED THYROID CANCER
Novel treatments - from PCR to patient
Mon 19 15:30
TEA & COFFEE
HALL Q
Mon 19 16:00
Oral Communications 2: REPRODUCTION AND BONE
QUEEN'S SUITE B
Chairs: A McNeilly (Edinburgh) & E Vasilopoulou (Birmingham)
Mon 19 16:00
OC2.1
Oral Communications 2: REPRODUCTION AND BONE
The expression of kisspeptin and kisspeptin receptor is altered in pre-eclampsia
Mon 19 16:15
OC2.2
Oral Communications 2: REPRODUCTION AND BONE
Contrasting effects of kisspeptin-10 between men and women reveal sexual dimorphism in the hypothalamic regulation of human reproduction
Mon 19 16:30
OC2.3
Oral Communications 2: REPRODUCTION AND BONE
Kissorphin, a hexapeptide derivative of kisspeptin, acts via neuropeptide FF receptors to inhibit cyclic adenosine monophosphate release but has no gonadotrophin-releasing hormone releasing activity
Mon 19 16:45
OC2.4
Oral Communications 2: REPRODUCTION AND BONE
ERβ and GPR30 mediate distinct and opposite oestrogenic influences on microglial phagocytosis of apoptotic neuronal cells
Mon 19 17:00
OC2.5
Oral Communications 2: REPRODUCTION AND BONE
Nutrient regulation of growth factor signalling in human placenta
Mon 19 17:15
OC2.6
Oral Communications 2: REPRODUCTION AND BONE
Identification of microRNAs involved in regulating growth factor signalling in the first trimester placenta
Mon 19 17:30
OC2.7
Oral Communications 2: REPRODUCTION AND BONE
Increased cardiovascular events in women with polycystic ovary syndrome: retrospective analysis of a large database
Mon 19 17:45
OC2.8
Oral Communications 2: REPRODUCTION AND BONE
A calcium-sensing receptor (CaSR) variant, Glu250Lys, present in familial hypocalciuric hypercalcaemia (FHH) and autosomal dominant hypocalcaemic hypercalciuria (ADHH) probands represents a functionally neutral polymorphism: lessons for CaSR mutational analysis
Mon 19 16:00
Symposium 5: SPRINT OR MARATHON? MUSCLING IN ON THE OLYMPICS
Muscle is recognised as important endocrine organ and target for the treatment of metabolic syndrome. This symposium will explore the breadth of our new understanding of basic metabolism and investigative clinical data that is currently emerging.
QUEEN'S SUITE A
Chairs: G Lavery (Birmingham) & N Morton (Edinburgh)
Mon 19 16:00
S5.1
Symposium 5: SPRINT OR MARATHON? MUSCLING IN ON THE OLYMPICS
Muscles and their myokines
Copenhagen, Denmark
Mon 19 16:30
S5.2
Symposium 5: SPRINT OR MARATHON? MUSCLING IN ON THE OLYMPICS
Exercise effects on fat metabolism and insulin sensitivity in human muscle
Mon 19 17:00
S5.3
Symposium 5: SPRINT OR MARATHON? MUSCLING IN ON THE OLYMPICS
Novel signalling mechanisms controlling glycogen homeostasis in muscle
Mon 19 17:30
S5.4
Symposium 5: SPRINT OR MARATHON? MUSCLING IN ON THE OLYMPICS
Mitochondrial dysfunction and muscle disease
Mon 19 16:00
Clinical Management Workshop 1: THE LATE CONSEQUENCES OF CANCER THERAPY IN ADULTS
Two million people in the UK are living with or beyond cancer. Many are at risk of endocrinopathy
SUPPORTED BY CLINICAL ENDOCRINOLOGY, DEVELOPED WITH THE SOCIETY FOR ENDOCRINOLOGY'S LATE EFFECTS OF CANCER THERAPY SPECIAL INTEREST GROUP
MAIN AUDITORIUM
Chairs: M Druce (London) & A Kennedy (Birmingham)
Mon 19 16:00
CM1.1
Clinical Management Workshop 1: THE LATE CONSEQUENCES OF CANCER THERAPY IN ADULTS
The follow up of cancer survivors
Mon 19 16:30
CM1.2
Clinical Management Workshop 1: THE LATE CONSEQUENCES OF CANCER THERAPY IN ADULTS
The impact of cancer treatment on pituitary function
Mon 19 17:00
CM1.3
Clinical Management Workshop 1: THE LATE CONSEQUENCES OF CANCER THERAPY IN ADULTS
The impact of cancer treatment on fertility and pregnancy
Mon 19 17:30
CM1.4
Clinical Management Workshop 1: THE LATE CONSEQUENCES OF CANCER THERAPY IN ADULTS
The late consequences of cancer therapy to the thyroid
Mon 19 18:00
BREAK
Mon 19 18:10
YOUNG ENDOCRINOLOGISTS' PRIZE LECTURES
MAIN AUDITORIUM
Chairs: K Chapman (Edinburgh) & A Grossman (London)
Mon 19 18:10
YEP1.1
YOUNG ENDOCRINOLOGISTS' PRIZE LECTURES
Challenging the dogma: Tissue specific regulation of insulin action
Mon 19 18:40
YEP1.2
YOUNG ENDOCRINOLOGISTS' PRIZE LECTURES
Quantifying in vivo extra-adrenal cortisol production and dysregulation in human metabolic disease
Edinburgh, UK
Mon 19 19:10
WELCOME RECEPTION
HALL Q
Mon 19 19:45
YOUNG ENDOCRINOLOGISTS' SOCIAL EVENING
HALL D
Tue 20 07:00
BREAKFAST
MAIN AUDITORIUM FOYER & QUEEN'S SUITE FOYER
Tue 20 07:15
MEET THE EXPERT 1
Therapeutic management of adults with CAH
SUPPORTED BY CLINICAL ENDOCRINOLOGY
QUEEN'S SUITE A
Chair: S Ahmed (Glasgow)
Expert: W Arlt (Birmingham)
Tue 20 07:15
MTE1
MEET THE EXPERT 1
Therapeutic management of adults with CAH
Tue 20 07:15
MEET THE EXPERT 2
Amiodarone
SUPPORTED BY CLINICAL ENDOCRINOLOGY
QUEEN'S SUITE B
Chair: A Weetman (Sheffield)
Expert: M Vanderpump (London)
Tue 20 07:15
MTE2
MEET THE EXPERT 2
Amiodarone
Tue 20 07:15
MEET THE EXPERT 3
Preventing and managing long term complications of acromegaly
SUPPORTED BY CLINICAL ENDOCRINOLOGY
MAIN AUDITORIUM
Chair: R Murray (Leeds)
Expert: K Meeran (London)
Tue 20 07:15
MTE3
MEET THE EXPERT 3
Preventing and managing long term complications of acromegaly
Tue 20 08:15
Symposium 6: INHIBITING STEROID ENZYMES TO TREAT COMMON DISEASE
Novel drugs targeting steroid synthesis and metabolism provide new avenues for treating human diseases
QUEEN'S SUITE A
Chairs: W Arlt (Birmingham) & S Alvarez-Madrazo (Glasgow)
Tue 20 08:15
S6.1
Symposium 6: INHIBITING STEROID ENZYMES TO TREAT COMMON DISEASE
Ageing gracefully - the role of 11beta-HSD1
Tue 20 08:45
S6.2
Symposium 6: INHIBITING STEROID ENZYMES TO TREAT COMMON DISEASE
Old drugs for new targets - CYP11B2 inhibitors for hypertension
Saarbrucken, Germany
Tue 20 09:15
S6.3
Symposium 6: INHIBITING STEROID ENZYMES TO TREAT COMMON DISEASE
Dual aromatase and steroid sulfatase inhibition in breast cancer
Tue 20 09:45
S6.4
Symposium 6: INHIBITING STEROID ENZYMES TO TREAT COMMON DISEASE
Potential prostate cancer drug target: bioactivation of androstanediol by conversion to dihydrotestosterone
Chapel Hill, USA
Tue 20 08:15
Oral Communications 3: OBESITY, THYROID AND ADDISON'S DISEASE
QUEEN'S SUITE B
Chairs: A Brooke (Exeter) & N Schoenmakers (Cambridge)
Tue 20 08:15
OC3.1
Oral Communications 3: OBESITY, THYROID AND ADDISON'S DISEASE
Metformin in obese children and adolescents (MOCA) trial
Tue 20 08:30
OC3.2
Oral Communications 3: OBESITY, THYROID AND ADDISON'S DISEASE
Post-prandial high fat intake leads to acute exposure to circulating endotoxin in type 2 diabetes mellitus subjects
Tue 20 08:45
OC3.3
Oral Communications 3: OBESITY, THYROID AND ADDISON'S DISEASE
Risk of diabetes, cancer, large vessel disease and mortality in young women with polycystic ovary syndrome: a retrospective databased analysis
Tue 20 09:00
OC3.4
Oral Communications 3: OBESITY, THYROID AND ADDISON'S DISEASE
Glucose absorption capacity of the mature adipose tissue is increased after Bardet-Biedl syndrome induced ciliary defect in adipocytes' precursors
Strasbourg, France
Tue 20 09:15
OC3.5
Oral Communications 3: OBESITY, THYROID AND ADDISON'S DISEASE
Steroidogenic function following B lymphocyte depletion therapy in new onset autoimmune Addison's disease
Newcastle, UK
Tue 20 09:30
OC3.6
Oral Communications 3: OBESITY, THYROID AND ADDISON'S DISEASE
GATA3 polymorphisms are associated with autoimmune Addison's disease
Tue 20 09:45
OC3.7
Oral Communications 3: OBESITY, THYROID AND ADDISON'S DISEASE
Subclinical hypothyroidism is associated with fatigue and impaired functional status in males in the Whickham 20-year follow up cohort
Tue 20 10:00
OC3.8
Oral Communications 3: OBESITY, THYROID AND ADDISON'S DISEASE
Dietary factors augment the ability of the proto-oncogene PBF to induce goitrogenesis and hyperplasia in vivo
Tue 20 08:15
Clinical Management Workshop 2: CONTROVERSIES IN AETIOLOGY AND MANAGEMENT OF OSTEOPOROSIS
SUPPORTED BY CLINICAL ENDOCRINOLOGY AND DEVELOPED WITH THE SOCIETY FOR ENDOCRINOLOGY'S BONE AND MINERAL SPECIAL INTEREST GROUP
MAIN AUDITORIUM
Chairs: S Orme (Leeds) & C Higham (Manchester)
Tue 20 08:15
CM2.1
Clinical Management Workshop 2: CONTROVERSIES IN AETIOLOGY AND MANAGEMENT OF OSTEOPOROSIS
Impact of lifestyle choices on skeletal health
Tue 20 08:45
CM2.2
Clinical Management Workshop 2: CONTROVERSIES IN AETIOLOGY AND MANAGEMENT OF OSTEOPOROSIS
Osteoporosis and metabolic bone disease in adolescence
Tue 20 09:15
CM2.3
Clinical Management Workshop 2: CONTROVERSIES IN AETIOLOGY AND MANAGEMENT OF OSTEOPOROSIS
Complications of antiresorptive agents

Unknown speaker

Holbæk, Denmark
Tue 20 09:45
CM2.4
Clinical Management Workshop 2: CONTROVERSIES IN AETIOLOGY AND MANAGEMENT OF OSTEOPOROSIS
New and emerging therapies for osteoporosis
Tue 20 10:15
TEA & COFFEE
HALL Q
Tue 20 10:40
SOCIETY FOR ENDOCRINOLOGY DALE MEDAL LECTURE
MAIN AUDITORIUM
Chair: J Buckingham (London)
Tue 20 10:40
PL1
SOCIETY FOR ENDOCRINOLOGY DALE MEDAL LECTURE
Estrogen receptor insensitivity: physiological and clinical consequences
Durham, USA
Tue 20 11:20
SOCIETY FOR ENDOCRINOLOGY HOFFENBERG INTERNATIONAL MEDAL LECTURE
MAIN AUDITORIUM
Chair: G Williams (London)
Tue 20 11:20
PL2
SOCIETY FOR ENDOCRINOLOGY HOFFENBERG INTERNATIONAL MEDAL LECTURE
Bone as endocrine organ
New York, USA
Tue 20 12:00
LUNCH & POSTERS
HALL Q
Tue 20 14:00
Oral Communications 4: Steroids
QUEEN'S SUITE A
Chairs: R Bernhardt (Saarbrucken, Germany) & F McManus (Glasgow)
Tue 20 14:00
OC4.1
Oral Communications 4: Steroids
Increased 11β-hydroxysteroid dehydrogenase type 1 activity is associated with the adverse expression of glucocorticoid target genes in ageing human skin

Unknown speaker

Leeds, United Kingdom
Tue 20 14:15
OC4.2
Oral Communications 4: Steroids
Age-dependent increase in the expression/activity of 11β-HSD1 in key metabolic tissues may underpin the ageing phenotype, notably sarcopenia
Tue 20 14:30
OC4.3
Oral Communications 4: Steroids
A hypomorphic H6PD allele is sufficient to rescue the skeletal myopathy but not the lack of 11β-HSd type-1 mediated glucocorticoid regeneration phenotypes of H6PDKO mice
Tue 20 14:45
OC4.4
Oral Communications 4: Steroids
Broad phenotypic spectrum of 17a-hydroxylase deficiency: functional characterisation of 4 novel mutations in the CYP17A1 gene
Tue 20 15:00
OC4.5
Oral Communications 4: Steroids
A novel repressor mechanism regulating fetal Leydig cell steroidogenesis, pertubation of which results in masculinization disorders
Tue 20 15:15
OC4.6
Oral Communications 4: Steroids
Fatty liver in a mouse model of congenital adrenal hyperplasia is driven by peroxisome proliferator-activated receptors
Tue 20 15:30
OC4.7
Oral Communications 4: Steroids
Glucocorticoids increase subcutaneous adipose tissue insulin sensitivity in vivo: a randomised double-blind, placebo controlled, cross over study
Tue 20 15:45
OC4.8
Oral Communications 4: Steroids
The role of a novel co-regulator in modifying the transcriptional activities of the glucocorticoid receptor
Tue 20 14:00
Symposium 7: LATITUDE: ENDOCRINE CONSEQUENCES OF HUMAN MIGRATION
As humans have migrated towards the poles, a number of changes have occurred to our endocrine systems which have allowed us to adapt to our new environment, particularly daily and seasonal changes in light intensity and duration. In this symposium we will explore those endocrine systems most affected by latitudinal light levels and our adaptations to overcome these changes
MAIN AUDITORIUM
Chairs: D Renshaw (London) & A McNeilly (Edinburgh)
Tue 20 14:00
S7.1
Symposium 7: LATITUDE: ENDOCRINE CONSEQUENCES OF HUMAN MIGRATION
The origins and evolution of lactase persistence
Tue 20 14:30
S7.2
Symposium 7: LATITUDE: ENDOCRINE CONSEQUENCES OF HUMAN MIGRATION
Melatonin, light and sleep in the Antartic
Tue 20 15:00
S7.3
Symposium 7: LATITUDE: ENDOCRINE CONSEQUENCES OF HUMAN MIGRATION
Cortisol and mood - coping with seasons
Tue 20 15:30
S7.4
Symposium 7: LATITUDE: ENDOCRINE CONSEQUENCES OF HUMAN MIGRATION
Resurgence of vitamin D deficiency rickets in the UK
Manchester, UK
Tue 20 14:00
Young Endocrinologists' Symposium: OBTAINING FUNDING AND NETWORKING FOR YOUNG ENDOCRINOLOGISTS
QUEEN'S SUITE B
Chairs: V Cabrera-Sharp (London) & S Mirczuk (London)
Tue 20 14:00
YE1.1
Young Endocrinologists' Symposium: OBTAINING FUNDING AND NETWORKING FOR YOUNG ENDOCRINOLOGISTS
Obtaining fellowship funding and networking
Leeds, UK
Tue 20 14:30
YE1.2
Young Endocrinologists' Symposium: OBTAINING FUNDING AND NETWORKING FOR YOUNG ENDOCRINOLOGISTS
Pathways in clinical academia, fellowships and networking
Birmingham, UK
Tue 20 15:00
YE1.3
Young Endocrinologists' Symposium: OBTAINING FUNDING AND NETWORKING FOR YOUNG ENDOCRINOLOGISTS
Career opportunities in the States
Tue 20 15:30
YE1.4
Young Endocrinologists' Symposium: OBTAINING FUNDING AND NETWORKING FOR YOUNG ENDOCRINOLOGISTS
Trials and tribulations of the university lecturer
Tue 20 16:00
TEA & COFFEE
HALL Q
Tue 20 16:30
Clinical Debate:
THIS HOUSE BELIEVES THAT ALL ADRENAL PATIENTS WITH INCIDENTALOMA WHO FAIL TO SUPPRESS CORTISOL AFTER DEXAMETHASONE SHOULD HAVE AN ADRENALECTOMY
MAIN AUDITORIUM
Chair: S Shalet (Manchester)
For: B Atkinson (Belfast) Against: P Stewart (Birmingham)
Tue 20 16:30
MEET THE EXPERT 1 - REPEAT
Therapeutic management of adults with CAH
SUPPORTED BY CLINICAL ENDOCRINOLOGY
HALL D
Chair: S Ahmed (Glasgow)
Expert: W Arlt (Birmingham)
Tue 20 16:30
MTE1
MEET THE EXPERT 1 - REPEAT
Therapeutic management of adults with CAH
Tue 20 16:30
Oral Communications 5: GROWTH, TUMOURS AND PITUITARY
QUEEN'S SUITE A
Chairs: J Webster (Sheffield) & V Smith (Birmingham)
Tue 20 16:30
OC5.1
Oral Communications 5: GROWTH, TUMOURS AND PITUITARY
Human growth is regulated by an ubiquitination pathway including CUL7, OBSL1 and CCDC8
Tue 20 16:45
OC5.2
Oral Communications 5: GROWTH, TUMOURS AND PITUITARY
A network analysis of gene expression through childhood highlights changes related to age and growth
Tue 20 17:00
OC5.3
Oral Communications 5: GROWTH, TUMOURS AND PITUITARY
Long term experience of 131I-MIBG therapy in the treatment of neuroendocrine tumours: has it improved survival and what are the long term sequelae?
Tue 20 17:15
OC5.4
Oral Communications 5: GROWTH, TUMOURS AND PITUITARY
Steroid metabolomics in adrenocortical carcinoma reveal mitotane as an inducer of CYP3A4 and an inhibitor of 5alpha-reductase activity with major implications for drug metabolism and hydrocortisone replacement
Tue 20 17:30
OC5.5
Oral Communications 5: GROWTH, TUMOURS AND PITUITARY
Role of the hypoxic signalling pathways in the histopathological prediction of malignancy in phaeochromocytomas and paragangliomas
Tue 20 17:45
OC5.6
Oral Communications 5: GROWTH, TUMOURS AND PITUITARY
SUMOylation genes in pituitary gonadotrophs: wrestling with GnRH signalling
Tue 20 18:00
OC5.7
Oral Communications 5: GROWTH, TUMOURS AND PITUITARY
The role of the familialpituitary adenoma gene, AIP, in the proliferative and invasive activity of a malignant pancreatic cell line
Tue 20 18:15
OC5.8
Oral Communications 5: GROWTH, TUMOURS AND PITUITARY
Control of GH and IGF1 in acromegaly in the UK: responses to medical treatment
Tue 20 16:30
Symposium 8: SMALL MOLECULES, BIG EFFECTS: THE EMERGING ROLE FOR MICRO RNAS
MicroRNAs have emerged in recent years as key regulators in cancer and endocrine disease. They dramatically modify gene expression at the post-transcriptional stage
QUEEN'S SUITE B
Chairs: M Westwood (Manchester) & S Wood (Glasgow)
Tue 20 16:30
S8.1
Symposium 8: SMALL MOLECULES, BIG EFFECTS: THE EMERGING ROLE FOR MICRO RNAS
MicroRNA: an introduction
Tue 20 17:00
S8.2
Symposium 8: SMALL MOLECULES, BIG EFFECTS: THE EMERGING ROLE FOR MICRO RNAS
MicroRNA regulation of the IGF axis
Leeds, UK
Tue 20 17:30
S8.3
Symposium 8: SMALL MOLECULES, BIG EFFECTS: THE EMERGING ROLE FOR MICRO RNAS
MicroRNA and the beta-cell
Berlin, Germany
Tue 20 18:00
S8.4
Symposium 8: SMALL MOLECULES, BIG EFFECTS: THE EMERGING ROLE FOR MICRO RNAS
MicroRNA in the diagnosis and therapy of endcorine cancers
Tue 20 17:15
MEET THE EXPERT 2 - REPEAT
Amiodarone
SUPPORTED BY CLINICAL ENDOCRINOLOGY
HALL D
Chair: A Weetman (Sheffield)
Expert: M Vanderpump (London)
Tue 20 17:15
MTE2
MEET THE EXPERT 2 - REPEAT
Amiodarone
Tue 20 18:40
SOCIETY FOR ENDOCRINOLOGY TRANSATLANTIC MEDAL
MAIN AUDITORIUM
Chair: P Stewart (Birmingham)
Tue 20 18:40
PL3
SOCIETY FOR ENDOCRINOLOGY TRANSATLANTIC MEDAL
Metabolism to epigenetics: the circadian clock link
Irvine, USA
Tue 20 19:40
CONFERENCE DINNER
ROYAL HALL
Wed 21 07:00
BREAKFAST
QUEEN'S SUITE FOYER
Wed 21 07:15
MEET THE EXPERT 4
Management of persistent TSH elevation in hypothyroid patients
SUPPORTED BY CLINICAL ENDOCRINOLOGY AND THE BRITISH THYROID FOUNDATION
QUEEN'S SUITE A
Chair: J Wass (Oxford)
Expert: A Allahabadia (Sheffield)
Wed 21 07:15
MTE4
MEET THE EXPERT 4
Management of persistent TSH elevation in hypothyroid patients
Wed 21 07:15
MEET THE EXPERT 5
The surgical approaches to MEN1 - what the endocrinologist needs to know
SUPPORTED BY CLINICAL ENDOCRINOLOGY
QUEEN'S SUITE B
Chair: S Ball (Newcastle)
Expert: B Harrison (Sheffield)
Wed 21 07:15
MTE5
MEET THE EXPERT 5
The surgical approaches to MEN1 - what the endocrinologist needs to know
Sheffield, UK
Wed 21 08:00
BREAKFAST
MAIN AUDITORIUM FOYER
Wed 21 08:10
SOCIETY FOR ENDOCRINOLOGY ANNUAL GENERAL MEETING
MAIN AUDITORIUM
Wed 21 09:00
Symposium 9: DEVELOPMENTAL PROGRAMMING OF ENDOCRINE DISEASE
It’s not what I eat, it’s what my mother ate. Can maternal lifestyle or nutrition programme life-long metabolic and endocrine problems in their offspring.
QUEEN'S SUITE A
Chairs: A Fowden (Cambridge) & O Brand (Oxford)
Wed 21 09:00
S9.1
Symposium 9: DEVELOPMENTAL PROGRAMMING OF ENDOCRINE DISEASE
Developmental programming of type 2 diabetes
Wed 21 09:30
S9.2
Symposium 9: DEVELOPMENTAL PROGRAMMING OF ENDOCRINE DISEASE
Neuroendocrine origins of obesity
Los Angeles, USA
Wed 21 10:00
S9.3
Symposium 9: DEVELOPMENTAL PROGRAMMING OF ENDOCRINE DISEASE
The foetus or the placenta? Targets of glucorticoid programming
Wed 21 10:30
S9.4
Symposium 9: DEVELOPMENTAL PROGRAMMING OF ENDOCRINE DISEASE
Obesity in pregnancy: implications for the next generation
Laramie, USA
Wed 21 09:00
Symposium 10:
CURRENT CONCEPTS AND MANAGEMENT OF PHAEOCHROMOCYTOMA
SUPPORTED BY THE ASSOCIATION FOR MULTIPLE ENDOCRINE NEOPLASIA DISORDERS
MAIN AUDITORIUM
Chairs: J Connell (Dundee) & U Srirangalingam (London)
Wed 21 09:00
S10.1
Symposium 10:
Genetics and epidemiology
Wed 21 09:30
S10.2
Symposium 10:
Molecular mechanisms of phaeochromocytoma and tumorigenesis
San Antonio, USA
Wed 21 10:00
S10.3
Symposium 10:
Laboratory assessment and diagnostic imaging
Nijmegen, The Netherlands
Wed 21 10:30
S10.4
Symposium 10:
Novel therapies for malignant phaeochromocytomas and paragangliomas
Paris, France
Wed 21 09:00
Nurses' Session 1:
THYROID EYE DISEASE
SUPPORTED BY THE THYROID EYE DISEASE CHARITABLE TRUST
QUEEN'S SUITE B
Chairs: D Wright (Bradford) & N Ellis (Bradford)
Wed 21 09:00
N1.1
Nurses' Session 1:
Thyroid Eye Disease - presentation and treatment
Wed 21 10:00
N1.2
Nurses' Session 1:
Thyroid Eye Disease
Wed 21 10:30
N1.3
Nurses' Session 1:
Thyroid Eye Disease
Wed 21 11:00
TEA & COFFEE
Wed 21 11:30
SOCIETY FOR ENDOCRINOLOGY EUROPEAN MEDAL LECTURE
MAIN AUDITORIUM
Chair: M Korbonits (London)
Wed 21 11:30
PL4
SOCIETY FOR ENDOCRINOLOGY EUROPEAN MEDAL LECTURE
GLP-1 therapy of type 2 diabetes - current status
Copenhagen, Denmark
Wed 21 12:00
SOCIETY FOR ENDOCRINOLOGY JUBILEE MEDAL LECTURE
MAIN AUDITORIUM
Chair: G Williams (London)
Wed 21 12:00
PL5
SOCIETY FOR ENDOCRINOLOGY JUBILEE MEDAL LECTURE
Acromegaly - improving outcomes
Wed 21 12:30
LUNCH
HALL Q
Wed 21 13:45
Symposium 11: NOVEL LESSONS FROM MINERALOCORTICOID EXCESS
Recent breakthroughs from the genetics of mineralocorticoid hypertension
QUEEN'S SUITE A
Chairs: E Davies (Glasgow) & E Nogueira (Birmingham)
Wed 21 13:45
S11.1
Symposium 11: NOVEL LESSONS FROM MINERALOCORTICOID EXCESS
A difficult TASK: murine models of mineralocorticoid excess
Regensburg, Germany
Wed 21 14:15
S11.2
Symposium 11: NOVEL LESSONS FROM MINERALOCORTICOID EXCESS
Human potassium channel mutations and mineralocorticoid hypertension
Paris, France
Wed 21 14:45
S11.3
Symposium 11: NOVEL LESSONS FROM MINERALOCORTICOID EXCESS
Long term consequences of primary hyperaldosteronism
Wed 21 15:15
S11.4
Symposium 11: NOVEL LESSONS FROM MINERALOCORTICOID EXCESS
Therapeutic options for mineralocorticoid hypertension
Wed 21 13:45
Symposium 12: MEDULLARY THYROID CANCER
Emerging knowledge of the molecular mechanisms in medullary carcinoma of the thyroid is improving our understanding of this condition, which is now impacting on therapy
MAIN AUDITORIUM
Chairs: D Bassett (London) & V Smith (Birmingham)
Wed 21 13:45
S12.1
Symposium 12: MEDULLARY THYROID CANCER
Molecular pathogenesis of MTC
Naples, Italy
Wed 21 14:15
S12.2
Symposium 12: MEDULLARY THYROID CANCER
RAS mutations in sporadic MTC
Lisbon, Portugal
Wed 21 14:45
S12.3
Symposium 12: MEDULLARY THYROID CANCER
The diagnosis and management of MTC
Wed 21 15:15
S12.4
Symposium 12: MEDULLARY THYROID CANCER
Novel targeted therapies for MTC
Paris, France
Wed 21 13:45
Nurses' Session 2:
ADDISON'S/PHAEOCHROMOCYTOMAS/CONN'S SYNDROME
QUEEN'S SUITE B
Chairs: S Gorick (Norwich) & V Kieffer (Leicester)
Wed 21 13:45
N2.1
Nurses' Session 2:
Conn's and phaeochromocytoma
Wed 21 14:15
N2.2
Nurses' Session 2:
Nursing case study on phaeochromocytoma
Wed 21 14:30
N2.3
Nurses' Session 2:
Introduction to Addison's
Wed 21 15:00
N2.4
Nurses' Session 2:
Day-to-day practice on management of steroid replacement
Wed 21 15:15
N2.5
Nurses' Session 2:
Living with Addison's
Wed 21 13:45
MEET THE EXPERT 8
Optogenetics: controlling cells with light
HALL D
Chair: R Andrew (Edinburgh)
Expert: R Allemann (Cardiff)
Wed 21 13:45
MTE8
MEET THE EXPERT 8
Optogenetics: controlling cells with light
Wed 21 14:45
MEET THE EXPERT 9
All you need to know about CHIP-sequencing
HALL D
Chair: C McCabe (Birmingham)
Expert: J Carroll (Cambridge)
Wed 21 14:45
MTE9
MEET THE EXPERT 9
All you need to know about CHIP-sequencing
Wed 21 15:45
TEA & COFFEE
HALL Q
Wed 21 16:15
AWARDS CEREMONY
MAIN AUDITORIUM
Chair: J Buckingham (London)
Wed 21 17:15
SOCIETY FOR ENDOCRINOLOGY MEDAL LECTURE
MAIN AUDITORIUM
Chair: J Buckingham (London)
Wed 21 17:15
PL7
SOCIETY FOR ENDOCRINOLOGY MEDAL LECTURE
Genetic, molecular and physiological mechanisms involved in human obesity
Wed 21 18:00
BRITISH THYROID ASSOCIATION PITT-RIVERS LECTURE
MAIN AUDITORIUM
Chair: G Williams (London)
Wed 21 16:45
PL6
BRITISH THYROID ASSOCIATION PITT-RIVERS LECTURE
The thyroid - too much and too little across the ages
Wed 21 18:00
Otsuka satellite symposium
Chair: P Bouloux (London)
Wed 21 18:00
OS1
Otsuka satellite symposium
Hyponatraemia in neurosurgical patients: insights and implications
Wed 21 18:45
OS2
Otsuka satellite symposium
Accelerating post-aneurysm recovery by correcting hypotraemia
Wed 21 18:00
How do we balance a 21st century medicine with a 21st century economy?
Thu 22 07:00
BREAKFAST
QUEEN'S SUITE FOYER
Thu 22 07:30
MEET THE EXPERT 6
Prioritising therapy in neuroendocrine tumours
SUPPORTED BY CLINICAL ENDOCRINOLOGY
QUEEN'S SUITE A
Chair: S Aylwin (London)
Expert: C Toumpanakis (London)
Thu 22 07:30
MTE6
MEET THE EXPERT 6
Prioritising therapy in neuroendocrine tumours
Thu 22 07:30
MEET THE EXPERT 7
Regulating periods and optimising fertility in PCOS
SUPPORTED BY CLINICAL ENDOCRINOLOGY
QUEEN'S SUITE B
Chair: H Randeva (Warwick)
Expert: C Duncan (Edinburgh)
Thu 22 07:30
MTE7
MEET THE EXPERT 7
Regulating periods and optimising fertility in PCOS
Thu 22 08:30
CLINICAL ENDOCRINOLOGY TRUST MEDAL LECTURE
Developing growth hormone agonists and antagonists for the clinic
SUPPORTED BY CLINICAL ENDOCRINOLOGY TRUST
MAIN AUDITORIUM
Chair: J Bevan (Aberdeen)
Thu 22 08:30
PL8
CLINICAL ENDOCRINOLOGY TRUST MEDAL LECTURE
Developing growth hormone agonists and antagonists for the clinic
Thu 22 09:00
CLINICAL ENDOCRINOLOGY TRUST VISITING PROFESSOR LECTURE
Long-term outcome and quality of life in patients with disorders of sex development
SUPPORTED BY CLINICAL ENDOCRINOLOGY TRUST
MAIN AUDITORIUM
Chair: J Connell (Dundee)
Thu 22 09:00
PL9
CLINICAL ENDOCRINOLOGY TRUST VISITING PROFESSOR LECTURE
Long-term outcome and quality of life in patients with disorders of sex development
Sao Paulo, Brazil
Thu 22 09:30
Funding opportunities: NIHR/MRC Efficacy and Mechanisms Evaluations (EME) Board
MAIN AUDITORIUM
Thu 22 09:30
FO1.1
Funding opportunities: NIHR/MRC Efficacy and Mechanisms Evaluations (EME) Board
Opportunities in translational research - the NIHR/MRC Efficacy and Mechanisms Evaluations (EME) Board
Oxford, United Kingdom
Thu 22 09:45
FO1.2
Funding opportunities: NIHR/MRC Efficacy and Mechanisms Evaluations (EME) Board
NIHR research networks: an update

Unknown speaker

Liverpool, United Kingdom
Thu 22 10:00
TEA & COFFEE
HALL Q
Thu 22 10:30
SENIOR ENDOCRINOLOGISTS' SESSION
HALL D
Thu 22 10:30
SE1.1
SENIOR ENDOCRINOLOGISTS' SESSION
Seeing the light
Thu 22 10:55
SE1.2
SENIOR ENDOCRINOLOGISTS' SESSION
It's time to identify the hormone that maintains bodty fat content
Thu 22 11:20
SE1.3
SENIOR ENDOCRINOLOGISTS' SESSION
UK stance on adult GH replacment maintains our isolation from Europe
Thu 22 11:45
SE1.4
SENIOR ENDOCRINOLOGISTS' SESSION
Assisted conception and developing low cost version for the developing world
Thu 22 12:10
SE1.5
SENIOR ENDOCRINOLOGISTS' SESSION
Tales from an arthritic endocrinologist - why does the endocrine dog not bark in the cytokine night?
Thu 22 12:35
SE1.6
SENIOR ENDOCRINOLOGISTS' SESSION
Psychopathology of false conviction
Montecastello di Vibio, Italy
Thu 22 10:30
Clinical Management Workshop 3: ADVANCES IN ASSESSMENT AND MANAGEMENT OF INFERTILITY
What the endocrinologist needs to know
SUPPORTED BY CLINICAL ENDOCRINOLOGY
QUEEN'S SUITE A
Chairs: W Dhillo (London) & J George (Edinburgh)
Thu 22 10:30
CM3.1
Clinical Management Workshop 3: ADVANCES IN ASSESSMENT AND MANAGEMENT OF INFERTILITY
Novel mutations causing infertility
Lausanne, Switzerland
Thu 22 11:00
CM3.2
Clinical Management Workshop 3: ADVANCES IN ASSESSMENT AND MANAGEMENT OF INFERTILITY
Semen analysis: what does it mean and can we improve it?
Thu 22 11:30
CM3.3
Clinical Management Workshop 3: ADVANCES IN ASSESSMENT AND MANAGEMENT OF INFERTILITY
How can we predict ovarian reserve and how useful is this?
Utrecht, The Netherlands
Thu 22 12:30
CM3.4
Clinical Management Workshop 3: ADVANCES IN ASSESSMENT AND MANAGEMENT OF INFERTILITY
The endocrine basis of what we do in the IVF clinic
Thu 22 10:30
Clinical Management Workshop 4: HOW DO I APPROACH...
Real world approaches to clinical dilemmas
SUPPORTED BY CLINICAL ENDOCRINOLOGY
MAIN AUDITORIUM
Chairs: J Bevan (Aberdeen) & A Paisley (Manchester)
Thu 22 10:30
CM4.1
Clinical Management Workshop 4: HOW DO I APPROACH...
Drug-induced hyperprolactinaemia
Thu 22 10:50
CM4.2
Clinical Management Workshop 4: HOW DO I APPROACH...
Endocrine assessment in HIV/AIDS
Thu 22 11:10
CM4.3
Clinical Management Workshop 4: HOW DO I APPROACH...
Neuroendocrine assessment in morbid obesity

Unknown speaker

Liverpool, United Kingdom
Thu 22 11:30
CM4.4
Clinical Management Workshop 4: HOW DO I APPROACH...
Endocrine evaluation in a patient with coeliac disease
Newcastle, UK
Thu 22 11:50
CM4.5
Clinical Management Workshop 4: HOW DO I APPROACH...
Hypogonadism in a man with cancer of the prostate
Thu 22 12:10
CM4.6
Clinical Management Workshop 4: HOW DO I APPROACH...
Endocrine evaluation in a patient with iron overload
Birmingham, UK
Thu 22 12:30
MEET THE EXPERT 5 - REPEAT
The surgical approaches to MEN1 - what the endocrinologist needs to know
SUPPORTED BY CLINICAL ENDOCRINOLOGY
MAIN AUDITORIUM
Chair: S Ball (Newcastle)
Expert: B Harrison (Sheffield)
Thu 22 12:30
MTE5
MEET THE EXPERT 5 - REPEAT
The surgical approaches to MEN1 - what the endocrinologist needs to know
Sheffield, UK
Thu 22 12:30
MEET THE EXPERT 4 - REPEAT
Management of persistent TSH elevation in hypothyroid patients
SUPPORTED BY CLINICAL ENDOCRINOLOGY AND THE BRITISH THYROID FOUNDATION
QUEEN'S SUITE B
Chair: J Wass (Oxford)
Expert: A Allahabadia (Sheffield)
Thu 22 12:30
MTE4
MEET THE EXPERT 4 - REPEAT
Management of persistent TSH elevation in hypothyroid patients
Thu 22 12:30
MEET THE EXPERT 3 - REPEAT
Preventing and managing long term complications of acromegaly
SUPPORTED BY CLINICAL ENDOCRINOLOGY
QUEEN'S SUITE A
Chair: R Murray (Leeds)
Expert: K Meeran (London)
Thu 22 12:30
MTE3
MEET THE EXPERT 3 - REPEAT
Preventing and managing long term complications of acromegaly
Thu 22 13:15
MEET THE EXPERT 7 - REPEAT
Regulating periods and optimising fertility in PCOS
SUPPORTED BY CLINICAL ENDOCRINOLOGY
QUEEN'S SUITE B
Chair: H Randeva (Warwick)
Expert: C Duncan (Edinburgh)
Thu 22 13:15
MTE7
MEET THE EXPERT 7 - REPEAT
Regulating periods and optimising fertility in PCOS
Thu 22 13:15
MEET THE EXPERT 6 - REPEAT
SUPPORTED BY CLINICAL ENDOCRINOLOGY
QUEEN'S SUITE A
Chair: S Aylwin (London)
Expert: C Toumpanakis (London)
Thu 22 13:15
MTE6
MEET THE EXPERT 6 - REPEAT
Prioritising therapy in neuroendocrine tumours

0 result(s) found.

Please wait...

     
      - 
     
     
     


    Abstracts from this event
      Abstracts from other events


          Session starts at:
          Abstract time:
        Event:


        Read full abstract